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1. Introduction 
According to the World Alzheimer Report 2015, 46.8 million people worldwide are suffered 
from dementia in 2015, and this number will reach 131.5 million in 2050 (Prince, 2015). In 
China, the people over 65 years old reached 143.9 million until the end of 2015 (Ministry of 
Civil Affairs of China, 2016), and this case was 33.8 million people in Japan (Ministry of 
Internal Affairs and Communications Statistics of Japan, 2015). Usually one in nine people over 
65 years old suffered from memory deficits (Hebert et al., 2013). Alzheimer's disease (AD) is 
a chronic progressive neurodegenerative disorder, and also is the most common cause of 
dementia and may contribute to 60-70% of the cases. However, the current clinical drugs for 
AD, such as rivastigmine and memantine, are employed for symptomatic therapy (Tan et al., 
2014) and unfortunately insufficient for improving cognitive function in patients with more 
severe impairments and are associated with an increased risk of adverse events (Tricco et al., 
2013). 
The main pathological characteristics of AD are extracellular Amyloid β (Aβ) plaques and 
intracellular neuroﬁbrillary tangles; while the neurite dystrophy and synapse loss also occur, 
and those underlie the pathogenesis of AD and are located upstream of neuronal death in the 
Aβ cascade (Dickson and Vickers, 2001; Terry et al., 1991). What’s more, axonal degeneration 
probably initiates the onset and progression of neuronal death in AD (Alobuia et al., 2013), so 
we consider the neuronal network reconstruction through axonal regeneration is critical for the 
fundamental therapies of AD. In this study, we aimed to find some effective compounds which 
could promote axonal elongation, and probably reverse the progression of AD. At the same time, 
we also try to explore the target molecule of the effective compounds, which might contribute 
to the discovery of new mechanism for AD improvement. 
Studies in our laboratory has demonstrated that several compounds derived from natural 
medicines enhanced memory function in normal mice and ameliorated memory deficits in 
5XFAD mice (Tohda et al., 2012; Tohda et al., 2013; Urano and Tohda, 2010), a murine AD 
model, which indicates that natural medicines are promising sources as the effective 
therapeutics for neurodegenerative disorders. It is difficult to investigate the signaling 
mechanism of herbal medicines, because of the diversity and complexity of constituents, multi-
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component interactions and multiple molecular targets. In vitro bioassay-guided isolation is 
usually used to narrow and identify active compounds and provides a way to clarify the 
mechanism of crude drugs (Koehn and Carter, 2005). However, due to the bio-metabolism of 
constituents after drug oral administration, such an in vitro assay might not always reveal the 
authentic active compounds in vivo (Wishart, 2016). For the development of a therapeutic drug 
of central nervous system (CNS), we have to consider the Blood-Brain-Barrier (BBB) 
permeability. In other words, the utilization of natural medicines to the treatment of CNS 
diseases is largely hindered by the limited knowledge of their metabolism, brain transfer of 
active metabolites, and molecular mechanisms initiated by the active compounds. Therefore, to 
clarify the mechanisms of natural medicines, the vital thing is addressing which metabolites are 
delivered to the brain.  
By the in vitro screening study, we found a crude drug, Drynaria Rhizome (DR), could 
enhance axonal growth after Aβ-induced axonal atrophy in primary cultured neurons (Yang et 
al., 2015). In chapter 1 of this thesis, we investigated the effect of DR on Aβ-induced axonal 
atrophy (in vitro) and memory deficits in 5XFAD, AD model transgenic mice (in vivo), showing 
that DR extract promotes axonal elongation in Aβ-treated neurons and ameliorates memory 
deficits in the 5XFAD mice. AD-like pathologies (Aβ plaques, PHF-tau, and degenerated axons) 
were also ameliorated by DR treatment (Yang et al., 2017). We then identified brain-penetrating 
metabolites after DR extract oral administration using LTQ Orbitrap Fourier Transform Mass 
Spectrometry (LTQ-Orbitrap-FT-MS/MS) analysis, and explored the activity of detected 
metabolites on axonal growth in cultured neurons and memory deficits in 5XFAD mice (Yang 
et al., 2017). We investigated the mechanism of naringenin-induced axonal regrowth (Yang et 
al., 2017). In chapter 2, we tried to identify active compounds in DR by bioassay-guided 
isolation (Yang et al., 2015). From my recent study (Yang et al., 2017), the isolated effective 
compounds didn’t consist with compounds identified in Chapter 1, and were ones shown as 
undelivered compounds to the brain. By comparing with ordinary bioassay-guided isolation, 
the methods defined in chapter 1 has advantages to identify the authentic effective substances 
in vivo. 
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Chapter 1 
Systematic strategy for identification of effective compounds from Drynaria Rhizome and 
clarification of the molecular mechanism for anti-Alzheimer’s disease 
 
2.1. Introduction 
The U.S. FDA has approved two kinds of medications to treat cognitive symptoms of AD, 
which are cholinesterase inhibitors (donepezil, rivastigmine, and galantamine), and NMDA 
antagonist (memantine). These clinical drugs provide temporary cognitive improvement in 
some AD patients. However, no treatment yet exists to halt or reverse the progression of AD-
related dementia. Currently, several AD drugs which are designed as anti-beta-amyloid 
(solanezumab), anti-tau aggregation (TauRx0237), and anti-inflammation (R-flurbiprofen) 
failed to rescue memory function in phase 3 trials (Le et al., 2016; Gauthier et al., 2016; Green 
et al., 2009). 
Neural circuits and network are responsible for memory generalization, consolidation and 
storage (Warburton and Brown, 2015; Xu and Südhof, 2013). Aβ-induced synapse loss, axonal 
degeneration and neuronal death are contributed to the disruption of neural networks which 
probably related to memory deficits (Jorge and Lennart, 2010). Therefore, we hypothesize the 
neuronal circuits reconstruction through axonal regeneration is critical for the fundamental 
therapies of AD.  
Traditional medicines are promising sources as the effective therapeutics for 
neurodegenerative disorders. In vitro bioassay-guided isolation is usually used to narrow and 
identify active compounds and provides a way to clarify the mechanism of crude drugs. 
However, due to the bio-metabolism of constituents after drug oral administration, such an in 
vitro assay might not always reveal the authentic active compounds in vivo.  
LC-MS analysis has been used as a useful tool for identification of constituents from the 
biosamples obtained after oral administration of herbal medicines (Xiao et al., 2012). On the 
basis of LC-TOF/MS analyses, a few reports have indicated that brain permeable metabolites 
might be used as interventions for AD (Ho et al., 2013; Wang et al., 2012), but their target 
proteins and mechanisms initiated by those metabolites were not well clarified. It is confirmed 
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by our laboratory and others that the drug affinity responsive target stability (DARTS) has been 
employed as an effective method in identifying the target protein of a ligand (Lomenick et al., 
2009; Tohda et al., 2012). Our laboratory has explored the signaling mechanisms of several 
small ligands by utilization of this method (Shigyo et al., 2015; Tohda et al., 2012). In the 
present study, we established a systematic strategy to identify brain-penetrating compounds 
after oral delivery of a drug and investigated the molecular mechanism of them combining LC-
MS and DARTS analyses. 
Here, we construct a systematic method to unravel the mechanisms of the natural medicines 
useful for AD therapies by identifying the brain permeable metabolites and their target proteins 
as an initial event. Briefly, the steps include (1) screening of effective natural medicines that 
may enhance axonal growth and ameliorate memory deficits using in vitro and in vivo models, 
which have been described previously (Kuboyama et al., 2005; Tohda et al., 2004); (2) 
systematically exploring effective metabolites delivered to the brain after drug administration 
using chemical and pharmacological analyses; (3) identification of the target proteins as an 
initial point in identifying the signaling axis of effective metabolites; and (4) clarification of the 
specific signaling pathway driven by those identified metabolites.  
The dried rhizomes of Drynaria fortunei (Kunze et Mett.) J. Sm. (Polypodiaceae), 
additionally known as “Drynaria Rhizome, DR”, is a widely distributed natural medicine in 
China, Korea, and Japan (Wagner et al., 2011). DR has the effect to tonify kidney, strengthen 
bones, and promote the healing of fractures (Chinese Pharmacopoeia Commission, 2010). 
Flavonoids are the main constituents of DR and show activities in animal experiments against 
osteoporosis, bone fractures, oxidative damage, and inflammation (Kuo et al., 2014; Sung et al., 
2012; Wong and Rabie, 2006; Wong et al., 2013). Our screening study showed the possibility 
that DR extract promoted axonal growth after Aβ-induced axonal atrophy (Yang et al., 2015).  
In this chapter, after the screening of natural medicines, we first found that DR was able to 
ameliorate memory deficits in an AD mice model. LTQ-Orbitrap-FT-MS/MS analysis 
pinpointed the authentic active compounds after oral administration of DR. Furthermore, we 
identified the target of the active metabolites by a combination of DARTS and LTQ-Orbitrap-
FT-MS/MS and clarified their mechanisms for axonal growth. We are the first to clarify the 
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effective form of DR and its mechanism as interventions for AD. 
 
2.2 Material and Methods 
   All the experiments involving animals were performed according to the Guidelines for the 
Care and Use of Laboratory Animals of the University of Toyama and the NIH Guidelines for 
the Care and Use of Laboratory Animals. By the Committee for Animal Care and Use of the 
University of Toyama, the confirmation number for the recombinant gene experiments is 
G2013INM-1, and the approval number for the animal experiments is A2014INM-1. 
 
2.2.1 Animals 
   ddY mice (6-week old, male) were purchased from SLC, Japan. Transgenic mice (5XFAD) 
were imported from Jackson Laboratory (Bar Harbor, ME, USA). They were maintained as 
double hemizygotes by crossing with B6/SJL F1 breeders. 5XFAD mice (male and female, 6–
8 months old) and non-transgenic wild-type littermate mice (male and female, 6–8 months old) 
were used to test the effect of the DR extract. To test the effect of naringenin on memory 
improvement, we used wild-type mice (male, 8–12 months old) and age-matched 5XFAD mice. 
All mice were housed on a 12-h light/dark cycle starting at 7:00 (25 ± 2°C), with free access to 
food and water. 
 
2.2.2 Antibodies 
   The primary antibodies for immunocytochemistry (ICC) and immunohistochemistry (IHC) 
included a mouse monoclonal antibody against phosphorylated neurofilament-H (pNF-H) 
(1:500 for ICC and 1:300 for IHC, SMI-35, Covance, Emeryville, CA, USA), a rabbit 
polyclonal antibody against microtubule associated protein 2 (MAP2) (1:2000, cat # ab32454, 
Abcam, Cambridge, UK), a rabbit polyclonal antibody against Aβ(1–40/42) (1:300, cat # 
AB5076, Chemicon, Temecula, CA, USA), a monoclonal antibody against paired helical 
filament (PHF)-tau (1:100, cat # MN1020, Thermo Scientific, Rockford, IL, USA), a polyclonal 
antibody against pThr514-collapsin response mediator protein 2 (CRMP2) (1:200, cat # 9397, 
Cell Signaling Technology), a monoclonal antibody against MAP2a/2b (1:200, cat # MS-249-
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S, Thermo fisher, Fremont, CA, USA), a polyclonal antibody against CRMP2 (1:3000, cat # 
C2993, Sigma, St. Louis, MO, USA), a polyclonal antibody against β-actin (1:1000, cat # 4967, 
Cell Signaling Technology). The secondary used antibodies were Alexa Fluor 488-conjugated 
goat anti-rabbit IgG (1:300), Alexa Fluor 594-conjugated goat anti-mouse antibody (1:300) 
(Invitrogen, Carlsbad, CA, USA), and HRP-conjugated goat anti-rabbit IgG (1:2000, cat # sc-
2004, Santa Cruz, CA, USA). 
 
2.2.3 Plant material 
   The D. fortunei rhizomes, which were collected in Zhejiang Province, China, were 
purchased from Tochimoto Tenkaido, Osaka, Japan. A voucher specimen was deposited as NMS 
no. 061814001 in the Institute of Natural Medicine, University of Toyama. The rhizomes were 
extracted with water, heated for 15 min until boiling, boiled for 1 h, filtered, and freeze-dried 
under reduced vacuum to yield an aqueous extract at a yield of 7.8%. 
 
2.2.4 Primary culture of cortical neurons and measurement of axonal and dendritic 
growth 
   Embryos were obtained from a pregnant ddY mouse (SLC, Shizuoka, Japan) at 14 days of 
gestation as described previously (Tohda et al., 2012). We dissected the cerebral cortices and 
removed the dura mater. The tissues were cut, digested, and cultured with Neurobasal medium 
(Gibco BRL, Rockville, MD, USA) containing 2 mM L-glutamine, 0.6% D-glucose, and 12% 
horse serum. The cells were seeded on FalconTM chambered 8-well slides (Franklin Lakers, NJ, 
USA) pre-coated with 5 µg/ml poly-D-Lysine (Sigma-Aldrich, St. Louis, MO, USA). The cells 
were incubated in a humidified incubator with 10% CO2 at 37°C. The seeding cell density was 
2.0 × 104 cells/cm2. The medium was replaced with Neurobasal medium containing 2% B-27 
(Gibco BRL) after 3-12 h neuronal culture.  
The neurons were treated with or without Aβ25−35 (10 µM) (A4559, Sigma-Aldrich) or 
Aβ1−42 (5 µM) (A9810, Sigma-Aldrich) for 3 days, after that the Aβ-contained medium was 
removed, and replaced with fresh medium containing DR extract, naringenin, narigenin-4’/7-
O-glucuronides, NGF or vehicle (H2O or DMSO) incubated for 4 days. The Aβ25−35 or 
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Aβ1−42 was previously incubated for 4 or 7 days at 37°C for aggregation, respectively. The 
neurons were fixed with 4% paraformaldehyde (PFA) for 1 h and preincubated for 24 h at 4°C 
with a pNF-H monoclonal antibody as an axonal marker and a MAP2 polyclonal antibody as a 
dendritic marker. Neurons were counterstained with 1 g/ml DAPI. Alexa Fluor 488-
conjugated goat anti-rabbit IgG and Alexa Fluor 594-conjugated goat anti-mouse IgG were used 
as secondary antibodies. Fluorescence images (644 μm × 855 μm) were captured using a 
fluorescence microscope system (BX61/DP70, Olympus). Using a MetaMorph analyzer 
(Molecular Devices, Sunnyvale, CA, USA), we measured the total length of the pNF-H-positive 
axons. The axonal density was calculated by the total axonal length dividing with neuronal 
numbers, and standardized against control. 
 
2.2.5 Behavioral test 
   The DR extract was dissolved in saline to concentrations of 0.5, 5, and 50 mg/ml. To 
investigate the effect of DR on memory improvement, we orally administered the DR extract 
or vehicle solution (saline) to the 5XFAD mice, once per day for 31 days (5, 50, 500 mg/kg per 
day). After 20 days of DR administration, mice were kept individually in an open-field box (33 
cm × 28 cm; height, 26.5 cm) for 10 min to habituate to the environment. A digital camera was 
used to track the paths of mice. The locomotor activity was evaluated by distance moved for 10 
min and was analyzed with Etho Vision 3.0 (Noldus, Wageningen, The Netherlands). After 21, 
25, and 31 days of DR administration, the object recognition memory test (ORT), object 
location memory test (OLT), and episodic-like memory test (ELM) were performed 
respectively as described previously (Kuboyama et al., 2015). Naringenin (Sigma-Aldrich, St. 
Louis, MO, USA) was suspended in saline to a concentration of 0.5 or 10 mg/ml. To test the 
effect of naringenin on memory improvement, we orally administered naringenin once per day 
for 31 days. On days 21, 22, and 29, the open-field locomotion test, ORT, and OLT were 
performed, respectively. 
   To test the effect of DR on memory enhancement in normal ddY mice, 50 mg/ml DR extract 
in saline or vehicle solution (saline) was orally administered for 7 days once per day (500 mg/kg 
per day). On day 7 of DR administration, locomotion test was performed, at the next day, ORT 
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was performed. On day 11 to 15, the mice were orally administered with DR extract again, and 
at the day 15, OLT was performed. 
 
2.2.6 Immunohistochemistry 
   After the behavioral studies, 5XFAD and wild-type mice were deeply anaesthetized with 
chloral hydrate (Wako, Tokyo, Japan), and perfused with saline followed by ice-cold 4% PFA. 
Isolated brains were post-fixed in 4% PFA for 24 h at 4°C, and then the brains were immersed 
with 30% sucrose for 48 h, and stored at –30°C for cryoprotection. Using a cryostat (Leica, 
Heidelberg, Germany), we cut the brains into 20 µm coronal slices (six slices of each mouse 
brain) in the perirhinal cortex area (bregma –1.46 to –2.06 mm). The slices were fixed with 4% 
PFA and stained with a polyclonal Aβ1–40/42 antibody, a monoclonal pNF-H antibody, and a 
monoclonal PHF-tau antibody at 4°C for 24 h. We used Alexa Fluor 488-conjugated goat anti-
rabbit (1:300) and Alexa Fluor 594-conjugated goat anti-mouse antibody (1:300) as secondary 
antibodies. Fluorescence images of Aβ1–40/42, axons, and PHF-tau were pictured using a 
fluorescent microscope (BX-61/DP70, Olympus, Tokyo, Japan) at a size of 324 µm × 430 µm. 
For quantification, 6 successive slices from the perirhinal cortex containing the hippocampus 
(CA1, CA3, and DG) of each mouse were captured. The images were analyzed with ImageJ 
(NIH, https://imagej.nih.gov/ij/) as described previously (Tohda et al., 2012). 
 
2.2.7 Bioavailability, metabolism, and brain penetration after DR extract administration 
DR extract was dissolved in water to a concentration of 10 mg/ml. A 10 l sample was 
injected to LC-MS after filtered with a 0.45 m membrane. To identify the metabolites that 
delivered to the brain, we orally administered DR or vehicle solution (saline) at a single dose 
to 5XFAD mice (male and female, n = 3) at a concentration of 13 g/kg. Mice were euthanized 
and blood was collected after 30 min or 5 h of DR administration. After centrifugation of blood 
at 11,000 g for 10 min at 4°C, the supernatant was collected as plasma. The brain cortex was 
collected following perfusion with saline. Plasma (200 l) was extracted with methanol (MeOH) 
(2 ml), dried under reduced pressure, and resolubilized in 50 l MeOH. The brain cortex was 
weighted homogenized with MeOH (Weight:Volume = 1:10), dried under reduced pressure, and 
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resolubilized in water (containing 0.1% formic acid) following applied to preactivated Sep-Pak 
C18 SPE cartridges (Waters, Milford, MA, USA). The samples were eluted with MeOH, vacuum 
dried, and resolubilized in MeOH, all the samples were filtered with 0.45 m membrane before 
injection to LC-MS. The standard curve was made to calculate the concentration of metabolites 
in the brain. In brief, the standard compounds were blended with blank cortex and extracted 
with MeOH as the method above, and then were applied to LC-MS. The chemical profiling of 
DR extract and biosamples were performed using a Thermo ScientiﬁcTM Accela HPLC system 
equipped with an LTQ Orbitrap XL hybrid Fourier Transform Mass Spectrometer (Thermo 
Fisher Co., San Jose, CA, USA). LC analysis was performed with a Capcell Pak C18 MGIII S-
5 (1.5 mm i.d. × 150 mm, Shiseido, Tokyo, Japan) column held at 40°C with a ﬂow rate of 200 
l/min. 0.1% aqueous formic acid (v/v) (A) and acetonitrile (B) were used as the mobile phase. 
The following linear gradient elution was used: 0–5 min, 6–20% B; 5–10 min, 20–30% B; 10–
25 min, 30–70% B; 25–26 min, 70–6% B; 26–32 min, 6% B. The following ESI parameters 
were used: spray voltage 4.5 kV, capillary voltage 40.0 kV, tube lens 150 V, capillary 
temperature 330°C, sheath gas ﬂow rate 50 units, and aux gas ﬂow rate 10 units. We operated 
the mass spectrometer in the positive ESI mode, scanning from 50 to 2,000 m/z, and a 
polytyrosine solution was used to calibrate the instrument before each experiment. 
 
2.2.8 DARTS analysis 
A mouse brain cortex (ddY, male, 6-week old) was dissected and homogenized with M-PER 
(Thermo Scientific) containing 1×protease inhibitor cocktail (Thermo Scientific). After 
centrifugation (14,000 g, 10 min, 4 °C), the supernatants (2.7 mg each) were mixed with 6 
mg/ml DR extract (60 l) or vehicle solution (H2O), and rotated for 60 min at room temperature. 
Thermolysin (2.7 mg, Sigma) was used to proteolyze proteins in reaction buffer [50 mM Tris-
HCl (pH 8.0), 50 mM NaCl, 10 mM CaCl2] for 30 min at 37°C. EDTA (0.5 M, pH 8.0) was 
added to stop the proteolysis in a 1:10 ratio of total volume. The samples (600 g each) were 
applied to 2D-PAGE and proteins were stained using colloidal Coomassie method. Compared 
the DR-treated group with vehicle-treated group, the spots that were in high density were cut 
out and prepared for mass spectrometry analysis. Gels containing proteins were excised, 
digested with trypsin (Promega, Madison, WI), mixed with α-cyano-4-hydroxycinnamic acid 
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in 50% acetonitrile/0.1% TFA, and subjected to MALDI-TOF MS (Microflex LRF 20, Bruker 
Daltonics).  
To confirm CRMP2 protein as a target of naringenin, DARTS and western blot analysis 
were performed. Primary cortical neurons (ddY, E14) was cultured for 72 h, after that the 
neurons were extracted with M-PER lysis buffer. After centrifugation (14,000 g, 10 min, 4 °C), 
the supernatants (15 g each) were mixed with 10 mM naringenin (1.67 l) or vehicle solution, 
and rotated for 60 min at room temperature. Each sample was proteolysed with 3.75 ng 
thermolysin in reaction buffer for 15 min at 37°C. To halt the proteolysis reaction, 0.5 M EDTA 
(pH 8.0) was added to each sample at a 1:10 ratio of total volume. Then, samples were reacted 
with 4×sample buffer at 95°C for 5 min, and were subjected to SDS-PAGE. After 
electrophoresis, the proteins were transferred to a nitrocellulose membrane, and blocked with 
4% non-fat milk in 0.1% Tween 20-containing TBS (T-TBS) for 1h at room temperature. The 
membrane was rinsed for once with T-TBS, and incubated with antibodies against CRMP2 
(1:3000) (Sigma, St. Louis, MO, USA, cat # C2993) and β-actin (1:1000) (Cell Signaling 
Technology, cat # 4967) in immunoreaction buffer (Can Get Signal solution 1) overnight at 4°C. 
After washing with T-TBS, the membrane was incubated with secondary antibody HRP-
conjugated goat anti-rabbit IgG (1:2000) (Santa Cruz, CA, USA, cat # sc-2004) in 
immunoreaction buffer (Can Get Signal solution 2) for 1h at room temperature. Using ECL 
prime reagent, the chemiluminescence signals on the membrane was detected in LAS4000. 
Signal intensity was quantified using a CS analyser (ATTO, version 3.0). 
 
2.2.9 IP coupled with LC-MS analysis 
Primary cultured mouse cortical neurons (E14) were seeded on 6-cm dishes at a density of 
1.5 × 105 cells/cm2 and incubated for 3 days. Then the neurons were treated with 100 M 
naringenin for 0.5, 2, or 6 h, respectively. After washing with 1× PBS for three times, neuronal 
cells were extracted with M-PER lysis buffer. Each of the cell lysates (30 g) was mixed under 
vortex, denatured and extracted with 100 l MeOH, after the centrifugation (14,000 g, 10 min, 
4 °C), the supernatant was collected, filtered with 0.45 m membrane, and 10 l of each was 
injected to LTQ-Orbitrap-FT-MS/MS.  
For immunoprecipitation, the neuronal lysates (30 g) treated with naringenin for 6 h were 
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incubated with CRMP2 antibody (Sigma, 3.5 g) or IgG (Santa Cruz, CA, USA, cat # sc-2027, 
3.5 g) for 1 h at 4°C, then the lysates were incubated for 10 min at 4°C with protein G 
dynabeads (30 l, Life Technologies). The protein G beads were washed three times with 1× 
PBS containing 0.02% Tween-20, and subsequently mixed and extracted with MeOH (200 l), 
sonicated for 20 min. The supernatant was collected after centrifugation (14,000 g, 10 min, 
4°C), and 10 l of each sample was applied to LTQ-Orbitrap-FT-MS/MS after filtration with 
0.45 m membrane.  
Except for the linear elution gradient: 0–5 min, 20–50% B; 5–20 min, 50–90% B; 20–21 
min, 90–20% B; 21–27 min, 20% B, the LTQ-Orbitrap-FT-MS/MS conditions were same as 
those in the aforementioned experiment.  
 
2.2.10 CRMP2 siRNA knockdown 
siRNAs were transfected into mouse cortical neurons (ddY E14) together with Green 
Fluorescent Protein (GFP) vectors according to the manufacturer’s protocol for nucleofection 
(Lonza, Bazel, Switzerland). In brief, mouse cortical neurons (5.0×106 cells) were mixed with 
a nucleofector solution and supplement (4.5:1, totally 100 l) containing siCRMP2 (1 M, 
Thermo Scientific, cat # 4390771) or control siRNA (1 M, Thermo Scientific, cat # 4390843) 
and GFP vector (2 g, Lonza, Bazel, Switzerland). The cell solutions were transferred to a 
cuvette, and electroporated with an Amaxa Nucleofector (Lonza). The neurons were seeded on 
an 8-well slide chamber. Three days after incubation, neurons were fixed with 4% PFA for 1 h 
at room temperature, and immunostained with a polyclonal antibody against CRMP2 (Sigma, 
cat # C2993) and counterstained with DAPI. Both GFP and DAPI positive immunostained 
neurons were selected for statistical analysis, the CRMP2 expression level in each cell body 
was quantified by CS analyser (ATTO, Tokyo, Japan). The appropriate concentration of siRNA 
was determined previously.  
To test the role of CRMP2 in naringenin-induced axonal growth, CRMP2 siRNA or control 
siRNA was transfected to the neurons with GFP vector, after cultured for 3 days, the neurons 
were treated with naringenin (10 M) or vehicle solution (0.1% DMSO). Four days after 
treatment, neurons were fixed with 4% PFA for 1 h and immunostained with antibodies against 
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pNF-H, the axonal length in GFP-positive neurons was measured by ImageJ analyser (NIH). 
 
2.2.11 In vitro evaluation of phosphorylated CRMP2 
CRMP2 phosphorylation was detected by immunocytochemical analysis. Mouse cortical 
neurons (E14) were cultured in 8-well chamber slides at a density of 2.0 × 104 cells/cm2 for 3 
days. In the immunocytochemical analysis, 10 M Aβ25−35 was treated for another three days. 
After Aβ-containing medium was removed, the neurons were administered with naringenin (1 
M) or vehicle solution (0.1% DMSO) for 0.5, 24, or 96 h, respectively. Neurons were fixed 
and immunostained with a rabbit anti-pThr514 CRMP2 antibody (1:200) (Cell Signaling 
Technology, cat # 9397) and a mouse anti-MAP2a/2b antibody (1:200, Fremont, CA, USA, cat 
# MS-249-S). Neurons were counterstained with 1 g/ml DAPI. Fluorescence images (644 μm 
× 855 μm) were captured using a fluorescence microscope system (BX61/DP70, Olympus). 
The expression of pCRMP2 was quantified using a CS analyser (ATTO, Tokyo, Japan). 
 
2.2.12 Statistical analysis 
   The data are shown as the mean ± SEM. The statistical analysis among groups were 
performed by Student’s unpaired t-test, one-way analysis of variance (ANOVA) with Dunnett’s 
post hoc test, and two-way ANOVA with Bonferroni post hoc test using GraphPad Prism 5 
(GraphPad Software, La Jolla, CA, USA), and P values less than 0.05 were seen as statistical 
significant.  
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2.3 Results 
2.3.1 DR extract promotes axonal regrowth in vitro and ameliorates memory deficits in 
the 5XFAD mouse model 
 
DR extract promotes axonal growth against Aβ25−35-induced axonal atrophy 
Aβ is hypothesized as a major pathological cause of AD, and Aβ25−35 is a partial fragment 
of a full peptide of Aβ. Our previous work has indicated that Aβ25−35 and Aβ1−42 lead to 
similar effects on axonal atrophy and neuronal death (Kuboyama et al., 2005), and was highly 
predictive of memory recovery in a murine AD model 5XFAD (Tohda et al., 2004; Kuboyama 
et al., 2005; Kuboyama et al., 2006). We investigated Aβ25–35-induced atrophy of axons and 
the recovery activity of DR extract in cultured mouse cortical neurons (Figure 1). Aβ25–35 (10 
µM) was administered to cortical neurons after 3 days incubation, and 3 additional days later, 
the medium was replaced with fresh medium including DR extract. After 4 days of DR 
administration, neurons were fixed with 4% PFA and immunostained for MAP2 and pNF-H 
(Figure 1A). Axonal density was significantly decreased by Aβ25–35 treatment, whereas 
treatment with DR (1 and 10 µg/ml) significantly increased the length of axons (Figure 1B and 
1C). NGF was clarified to induce the extension of axons after Aβ25–35 treatment (Kuboyama 
et al., 2005). We also evaluated the effect of DR extract on axonal growth in normal cultured 
neurons without Aβ treatment (Figure 2A). DR-treated group showed an increased trend of 
axonal length but not significant differences, while the positive control NGF significantly 
increased axonal growth compared with control (Figure 2B). 
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Figure 1. Effects of the aqueous extract of DR on axonal and dendritic elongation against 
Aβ25–35-induced neurite atrophy. Cortical neurons were cultured for 3 days, and then 10 µM 
Aβ25–35 or vehicle (H2O) were administered to the cells. Three days later, NGF (100 ng/ml), 
DR extract (1 or 10 µg/ml), or Veh (H2O) was treated to neurons after removing Aβ25–35. 
Neurons were immunostained (ICC) for pNF-H and MAP2 after 4 days treatment. The lengths 
of neurites were measured. (A) Time schedule of the experiments. (B) Quantification of total 
axonal and dendrite outgrowth per neuron. (C) Representative images of pNF-H and MAP2-
positive neurites. Values represent means ± SEM. [*p < 0.05, **p < 0.01, ***p < 0.001 vs. Veh 
(one-way ANOVA post hoc Dunnett’s test, n = 30-40 photographs)].  
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Figure 2. Effects of the aqueous extract of DR on axonal and dendritic extension in normal 
neurons. Primary cultured cortical neurons at 3 days in vitro, DR extract (1 or 10 µg/ml), NGF 
(100 ng/ml), or Cont (H2O) was treated for 4 days, the cells were fixed and immunostained for 
MAP2 and pNF-H. The lengths of pNF-H and MAP2 positive neurites were measured. (A) 
Time course of the experiments. (B) Quantification of total axonal and dendrite outgrowth per 
neuron. Values are means ± SEM of data. [*p < 0.05, ***p < 0.001 vs. Cont (one-way ANOVA 
post hoc Dunnett’s test, n = 26-33 photographs)].  
 
DR extract ameliorates memory deficits in a model of 5XFAD mice 
5XFAD mice co-expressed five FAD mutations [APP I716V (Florida), K670N/M671L 
(Swedish), V717I (London), and PS1 M146L, L286V] and developed Aβ plaques at 2 months 
of age, while the other types of AD mice showed a relatively long time (9 months) to form Aβ 
plaques (Oakley et al., 2006). The 5XFAD mice also showed spatial memory impairment at an 
early age of 4-5 months, as demonstrated by Y-maze memory test (Oakley et al., 2006), 
contextual fear conditioning test (Ohno, 2009), and object recognition memory test (Joyashiki 
et al., 2011). 
To test the effect of DR extract on memory improvement, we orally administered DR extract 
or vehicle solution to 5XFAD mice at doses of 5, 50 or 500 mg/kg per day. The determination 
of DR doses was based on the animal study of some other reports (Anuja et al., 2010; Lee et al., 
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2014). The memory test schedule was shown in Figure 4A. The object recognition memory test 
(Figure 4C and 4D) was based on mouse prefer to explore the novel object rather than the 
familiar one. In the training session, the mice equally explore each of the two objects, so the 
equivalent exploratory indices were the same (approximately 50%). In the test session, the 
exploring indices to novel object were increased by the wild-type mice and DR 50 or 500 
mg/kg-treated 5XFAD mice compared with vehicle-treated 5XFAD mice, which means vehicle 
5XFAD mice showed memory deficits compared with wild type mice, while after DR treatment, 
the object recognition memory was recovered in a dose dependent manner. The amelioration of 
novel object recognition memory after DR administration (p.o., 500 mg/kg) was confirmed by 
other independent experiments, too (Figure 4E and 4F). After 20 days of DR administration, 
the locomotion test was performed, among the five groups, there is no significant differences 
in the velocity and distances moved (Figure 3B and 4B). During the DR administration, the 
body weights were recorded, and there are no significant changes among of those five groups 
(Figure 3A).  
 
 
Figure 3. The effect of DR extract on body weight and velocity in 5XFAD mice. (A) The body 
weight of wild-type mice and 5XFAD mice (p > 0.05, drug × day interaction analysed by 
repeated two-way ANOVA post hoc Bonferroni test, n = 3–5 mice). (B) The velocity (within 
10 min) in the open field test (One-way ANOVA post hoc Dunnett’s test, n = 3–5 mice). 
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Figure 4. DR extract ameliorates recognition memory deficits in 5XFAD mice. (A) Time 
schedule of the experiments in B-D. Six- to 8-month-old 5XFAD and wild-type mice were used 
(n = 3–5). (B) Total distance moved (within 10 min) in the open field test. (C, D) Object 
recognition test. p < 0.0001, drug × time interaction was analyzed using repeated measures two-
way ANOVA, F(4, 15) = 13.18. *p < 0.05, post hoc Bonferroni test. (E, F) Repeated 
experiments of DR extract on the recognition memory function in 5XFAD mice. (E) Six- to 14-
month-old 5XFAD and wild-type mice were used (n = 3). The preference indices were 
quantified. p = 0.012, drug × time interaction was analyzed using repeated measures two-way 
ANOVA, F(2, 6) = 10.04. *p < 0.05, post hoc Bonferroni test. (F) Eight-month-old 5XFAD and 
wild-type mice were used (n = 4). The preference indices were quantified. p = 0.135, drug × 
time interaction was analyzed using repeated measures two-way ANOVA, F(2, 7) = 2.70. *p < 
0.05, post hoc Bonferroni test. 
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To investigate the effect of DR on spatial memory in 5XFAD mice, the object location 
memory test was performed after 25 days of DR administration (Figure 5A). In the test session 
of object location test, one of the object was moved to a new place, the vehicle-treated 5XFAD 
mice failed to distinguish the object in the novel location from the object with the familiar 
location. The exploratory indices to the novel placed object were significantly increased in wild-
type and DR (500 mg/kg)-treated 5XFAD mice, which means the location memory was 
recovered after high dose of DR administration. The episodic-like memory test was designed 
to evaluate the integrative ability of object (what), location (where), and context recognition 
(when) to mice (Dere et al., 2005). Two sets (4 same objects of each set) of objects were used 
in training session 1 and 2, the interval time was set for 10 min. In the test session, E1 and E4 
were placed at the same location in training session 2, while the objects D2 and D4’ had been 
presented to mice in training session 1 (Figure 5B). Therefore, objects D2 and D4’ were more 
unfamiliar than objects E1 and E4 in the test session. After DR (50 and 500 mg/kg) 
administration to the 5XFAD mice, the exploratory indices to unfamiliar objects (D2 and D4’) 
were significantly increased compared with the familiar objects (E1 and E4) (Figure 5C). The 
vehicle-treated 5XFAD mice failed to distinguish presented objects in the test session. In the 
test session, D2 was presented to mice at the same location in training session 1. D4’ was located 
at a novel place for the mice; therefore, if the object places and presentation orders were 
memorized, the mouse would show higher preference indices for object D4’ than D2. Like the 
vehicle-treated 5XFAD mice, even the wild-type mice could not recognize objects D2 and D4’. 
The exploratory indices to object D4’ after DR (500 mg/kg) administration were significantly 
increased compared with that to object D2 (Figure 5D), it is possible due to the memory 
enhancement of DR on normal mice (Figure 6A-6E).  
Collectively, these results demonstrated that memory deficits were rescued after orally 
administered DR extract to 5XFAD mice. 
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Figure 5. DR extract rescues object location and episodic-like memory deficits in 5XFAD mice. 
Six- to eight-month old 5XFAD and age-matched wild-type mice were used (n = 3–5). (A) 
Object location memory test. The exploring times of objects C1 and C1’ were quantified. p = 
0.007, drug × time interaction was analyzed using repeated measures two-way ANOVA, F(4, 
15) = 5.34. *p < 0.05, post hoc Bonferroni test. (B) Time schedule of episodic-like memory test. 
(C) The exploratory indices for objects (D4’ plus D2) were quantified. *p < 0.05, one-way 
ANOVA post hoc Bonferroni test. (D) The exploratory indices for objects D2 (black columns) 
and D4’ (red columns). #p < 0.05, two-way ANOVA post hoc Bonferroni test. *p < 0.05, one-
way ANOVA post hoc Bonferroni test. 
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Figure 6. DR extract enhances memory function in normal mice. The effect of DR extract on 
the memory function in normal mice (A-C). DR (500 mg/kg, p.o.) or vehicle (saline) was 
administered to mice for 7 days (males, 6 weeks old, n = 5 mice each group). On the day 8 and 
day 15, object recognition and object location test were started, the interval time between 
training and test was 48 h. The preference indices of the training and test sessions are shown. 
(A) Time course of the experiments. (B) Object recognition test. p = 0.09, drug × time 
interaction was analysed using repeated measures two-way ANOVA, F(1, 8) = 3.58. *p < 0.05, 
post hoc Bonferroni test. (C) Object location test. p = 0.005, drug × time interaction was 
analysed using a repeated measures two-way ANOVA, F(1, 8) = 14.38. *p < 0.05, post hoc 
Bonferroni test. (D) Total distance moved (10 min) in the open field test. (E)The body weight 
of ddY mice (p > 0.05, drug × day interaction analysed by repeated two-way ANOVA post hoc 
Bonferroni test, n = 5 mice). 
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DR extract ameliorates AD-like pathology in 5XFAD mice 
After behavioral tests, the wild-type and 5XFAD mice were euthanized. To test the effect 
of DR on the pathological changes in 5XFAD mice, we measured the number of Aβ plaques in 
sectioned brain slices using immunohistochemical analysis. Aβ1−42 antibody was used to 
visualize Aβ plaques, Aβ plaques were detected in the perirhinal cortex and hippocampus of the 
5XFAD mice brain, while no Aβ deposits were observed in the age-matched wild-type mice 
(Figure 7). Aβ plaques were reduced in the cortex of 5XFAD mice after DR administration in 
a dose dependent manner. High dose of DR administration (500 mg/kg) also induced Aβ plaques 
reduction in the hippocampus (Figure 8A and 8B). 
   To investigate the effect of DR on expressed level of PHF-tau, another key AD pathological 
feature, we performed immunohistochemical analysis with an anti-phosphorylated tau antibody 
using the brain slices. In the wild-type mice, we couldn’t detect any positive PHF-tau staining; 
while in the 5XFAD mice, PHF-tau was observed closely to the Aβ deposites (Figure 8A). DR 
decreased the levels of PHF-tau associated with Aβ plaques in the cortex dose dependently, the 
levels of PHF-tau associated with Aβ plaques showed a decreasing trend in the hippocampus 
after DR extract administration (Figure 8C). 
   As DR enhanced axonal growth against Aβ25−35-induced axonal atrophy in cultured 
cortical neurons (Yang et al., 2015), we evaluated whether DR administration induced any 
changes to axons in 5XFAD mice. Degenerated structure of axons, such as ring- or bulb-like 
neurofilaments, are localized within amyloid plaques in both preclinical and end-stage AD 
patients (Dickson and Vickers, 2001). In our previous study, we also showed the phenomenon 
that ring-shaped axons are colocalized with amyloid plaques in 5XFAD mice (Tohda et al., 
2012). The extension of axons was blocked at the front of Aβ plaques and degenerated axons 
formed swollen ring- or bulb-like shapes in the vehicle-treated 5XFAD mice (Figure 8D). 
Degenerated axons were hardly observed in the remote area of Aβ plaques. After DR (500 
mg/kg) administration, swollen axonal areas associated with Aβ plaques in the brain cortex and 
hippocampus were significantly decreased (Figure 8E).  
In conclusion, these results demonstrate that DR effectively repairs degenerated axons in 
the brains of 5XFAD mice, and ameliorates AD pathologies (Aβ plaques, PHF-tau) at the same 
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time, which might contribute to the recovery of cognitive function. 
 
 
Figure 7. DR extract decreases Aβ plaques in 5XFAD mice. Representative images of  
Aβ 1-40/42-positive plaques in perirhinal cortex and hippocampus. Scale bar, 1 mm. 
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Figure 8. DR extract reduces AD-like pathologies in 5XFAD mice. Vehicle solution (saline) or 
DR extract (5, 50, 500 mg/kg, p.o.) was administered to wild-type or age-matched 5XFAD mice 
(males and females, 6-8 months old) for 31 days. The day after the behavioral test, brain slices 
were made for immunohistochemical analysis. (A) Representative images of Aβ1−40/42-
positive plaques and PHF-tau associated with Aβ plaques in the perirhinal cortex. (B) 
Quantified result of the total Aβ plaques area per 100 µm2 in the perirhinal cortex and 
hippocampus. (C) Quantified result of PHF-tau area associated with Aβ plaques per 100 µm2 
in the perirhinal cortex and hippocampus. (D) Aβ plaques and axons were double 
immunostained with Aβ1−40/42 and pNF-H antibodies. Representative images in the perirhinal 
cortex showed bulb- or ring-like pNF-H-positive degenerated axons were colocalized with Aβ 
plaques. (E) Quantified result of total abnormal axons area per 100 µm2 of Aβ plaque in the 
perirhinal cortex and hippocampus. Statistical analyses were performed by one-way ANOVA 
and Dunnett’s post hoc test (*p < 0.05 vs. veh/5XFAD; the number of measured areas is shown 
in each column). 
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2.3.2 DR-derived metabolites access to the brain and ameliorate axonal atrophy and 
memory deficits 
 
DR-derived metabolites access to the brain after DR extract administration to 5XFAD 
mice 
   To clarify the mechanism of DR-induced axonal growth and memory improvement, and 
with the consideration of bio-metabolism and metabolites tissue distribution, we tried to 
identify metabolites that are delivered into the brain after DR oral administration. Using the 
high-accuracy LTQ-Orbitrap-FT-MS/MS analysis with quasi-molecular ion ([M+H]+) and 
within a mass error of ±1 mmu, we comprehensively characterized 17 compounds from DR 
extract by comparing their fragmentation patterns and MS/MS data with those of reference 
standards or reported compounds (Figure 9 and Table 1).  
 
 
 
Figure 9. HPLC-FTMS base peak ion chromatogram of the DR extract in the positive ESI mode. 
The numbers in each parenthesis correspond to the chemicals listed in Table 1. 
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Table 1. Compounds identified in DR extract and metabolites that were transferred in plasma and brain following oral administration of 
DR in 5XFAD mice. 
Peak No. and 
Metabolites 
RT 
(min) 
MS/MS Fragments Molecular 
Formula 
[M+H]+ 
(m/z) 
Identified Compound 
DR Plasma Brain 
1 5.59 181.0496 C15H18O9 343.1025 Caffeic acid-4-O-glucoside + +(0.5h) - 
2 6.06 579.1496 (427.0313, 
409.0839, 291.1580, 
289.0319, 247.1223), 
289.0708(271.0996, 
163.0733, 127.1166) 
C30H26O12  579.1496 Proanthocyanidin B 
+ - - 
3 6.86 341.0869, 179.0339 C21H26O13 487.1447 5,7-dihydroxychromone-7-neohesperidoside 
+ 
+(0.5, 
5h) 
- 
4 7.70 449.1080, 287.0552 
(269.1473, 241.1353, 
213.0526, 165.1339, 
153.0798) 
C27H30O15 
 
595.1658 Kaemperol-3-O-rutinoside 
+ - - 
5 8.35 287.0551 (269.0333, 
259.0746, 241.1809, 
231.0298, 153.1035) 
C27H30O15 
 
595.1657 Kaemperol-7- neohesperidoside 
+ - - 
6 9.17 451.1239, 435.1290, 
289.0710(163.0673, 
153.1316), 153.0183 
C27H32O15 597.1818 Neoeriocitrin 
+ 
+(0.5, 
5h) 
- 
7 9.40 419.0974, 287.0551 
(153.0846) 
C27H30O15 
 
595.1657 Luteolin-7-neohesperidoside 
+ - - 
8 10.39 435.1287, 419.1339, 
273.0757(153.0337, 
147.0683), 153.0182 
C27H32O14 581.1866 Naringin 
+ 
+(0.5, 
5h) 
- 
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Table 1. (Continued) 
9 10.66 287.0550 (269.1468, 
258.0283, 241.1390, 
231.1378, 213.1349, 
165.0254, 153.0266) 
C21H20O11 449.1080 Kaemperol-3-O-glucoside 
+ - - 
10 10.81 273.0761(153.0331, 
147.0550) 
C21H22O10 
  
435.1289 Naringenin-7-O-glucoside 
+ +(0.5h) - 
11 11.08  C9H6O4 179.0339 5,7-dihydroxychromone 
+ 
+(0.5, 
5h) 
- 
M1 5.47 179.0335 C15H14O10 355.0654 5,7-dihydroxychromone-glucuronide 
- 
+(0.5, 
5h) 
- 
M2 9.55 179.0334 C9H6O7S 258.9900 5,7-dihydroxychromone-sulfate 
- 
+(0.5, 
5h) 
- 
M3 9.55, 
10.40, 
10.92 
289.0699 C21H20O12 465.1010 Eriodictyol-glucuronide 
- 
+(0.5, 
5h) 
- 
M4 10.65  273.0750 C21H20O11 449.1063 Naringenin-7-O-glucuronide 
- 
+(0.5, 
5h) 
+(5h) 
M5 11.18 273.0750 C21H20O11 449.1063 Naringenin-4’-O-glucuronide 
- 
+(0.5, 
5h) 
+(5h) 
M6 12.36 273.0750 C21H20O11 449.1063 Naringenin-chalcone-glucuronide 
- 
+(0.5, 
5h) 
- 
17 12.01 287.0551(269.0756, 
258.0622, 241.0635, 
231.0604, 
213.0176,165.0438, 
153.0968), 179.0339 
C21H19O10 433.1129 Kaemperol-3-O-rhamnoside 
+ - - 
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Table 1. (Continued) 
18 13.03 287.0551 (269.1929, 
258.1298, 241.1409, 
213.0502, 165.0406, 
153.0382) 
C20H18O10 419.0974 Kaempferol 3-O-arabinoside 
+ - - 
19 14.04  163.0673, 153.1316 C15H12O6 289.0710 Eriocictyol + - - 
20 14.40  269.1717, 153.0713 C15H10O6 287.0552 Luteolin + - - 
21 (M7) 16.15  153.0658, 147.1258 C15H12O5 273.0760 Naringenin + +(5h) +(5h) 
22 16.70 287.0760, 269.1448, 
241.1417, 213.2002, 
165.0957, 153.0219 
C15H10O6 287.0551 Kaempferol 
+ - - 
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The two main compounds in DR extract are naringin and neoeriocitrin, with contents of 
96.8 and 108.0 mg g-1, respectively. Naringenin was a minor constituent in DR extract with a 
content at 0.27 mg g-1. Naringin was reported metabolized to naringenin and naringenin 
glucuronide after oral administration and the metabolites were detected in the plasma of rats 
(Fang et al., 2006). Then, using LTQ-Orbitrap-FT-MS/MS analysis, we profiled the chemicals 
that were delivered into the blood and brain in 5XFAD mice after DR oral administration. 
Generally speaking, it is better to use higher doses than effective doses to detect the metabolites 
in biosamples after administration of herbal extracts (Xiang et al., 2011), formulations 
(Fujiwara et al., 2011; Kushida et al., 2013), and even single compounds (Durairajan et al., 
2012; Tan et al., 2013). Thereby, a high dose of DR (13 g/kg) was singly oral administered to 
the 5XFAD mice. After 0.5 or 5 h of DR administration, the blood and brain biosamples were 
analysed by LTQ-Orbitrap-FT-MS/MS analysis. With the utilization of SIEVE software (Niu et 
al., 2015), we performed differential analyses of the total ion current (TIC) chromatograms for 
the biosamples from vehicle-treated and DR-treated mice (Figure 10).  
 
 
Figure 10. Differential analyses of total ion current (TIC) chromatogram between vehicle 
treated (red) and DR (13 g/kg) treated (blue) 5XFAD mice biosamples. DR extract (13 g/kg, 
p.o.) or vehicle solution (saline) was singly administered to mice (males and females, 12 months 
old, n = 3). Five hours after treatment, mice were sacrificed and the brain cortex was extracted 
with MeOH and applied to LC/MS analyses. The TICs were compared by SIEVE software. 
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Based on the retention times, mass values, and MS/MS fragments, we compared the TICs 
between vehicle or DR-treated biosamples. We detected 13 compounds or metabolites in the 
plasma, and 3 chemicals in the brain cortex of DR-treated 5XFAD mice (Table 1 and Figure 
11). Figure 12 showed the extracted ion current (EIC) chromatograms of the speculated DR-
derived metabolites. After administration of DR for 5 h, the metabolites were detected in the 
brains (Figure 12A(3)) but not in the brains of vehicle-treated 5XFAD mice (Figure 12A(1)) 
or 30 min after DR administration (Figure 12A(2)). We speculate the metabolites as naringenin 
and naringenin glucuronides based on the MS data. To confirm structures of the speculated 
metabolites, naringenin-7-O-glucuronide and naringenin-4’-O-glucuronide were synthesized 
from naringenin (TopuBio research, Toyama, Japan) and we analysed the mass fragmentation 
characteristics of them (Figure 11). The HPLC-MS results showed similar MS/MS 
fragmentations and retention time between the standards and DR-treated mouse brain samples 
(Figure 12B). Our pre-experiment showed that the Cmax of metabolites was 5 h after DR 
administration. Using the standard curve, we calculated the concentrations of naringenin, 
naringenin-7-O-glucuronide, and naringenin-4’-O-glucuronide metabolite in the brain after DR 
administration as 15.1 ± 2.9, 302.6 ± 77.9, and 22.7 ± 17.8 pmol/g, respectively. Taken together, 
the results indicate that the metabolites naringenin and naringenin-7/4’-O-glucuronide can 
penetrate the BBB after DR extract oral administration. 
 
 
Figure 11. Proposed structures of 3 metabolites existed in the brain after DR administration 
and characteristics of mass fragmentation of naringenin glucuronide. 
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Figure 12. Brain-penetrating metabolites after DR administration to 5XFAD mice. Vehicle 
solution (saline) or DR extract (13 g/kg, p.o.) was singly administered to 5XFAD mice (male 
and females, 12 months old, n = 3). Brain cortex was dissected 0.5 or 5 h after treatment, and 
was extracted with MeOH and applied to LC-MS analysis. (A) Extracted ion current (EIC) 
chromatograms of naringenin (m/z 273.0751) and naringenin glucuronide (m/z 449.1065). 
(A(1)) Blank without DR administration; (A(2)) 0.5 after DR administration; (A(3)) 5 h after 
DR administration. (B) Comparison of EIC chromatograms for naringenin-7/4’-O-glucuronide, 
naringenin, and naringin standards with brain samples obtained 5 h after DR administration. 
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DR-derived brain-penetrating metabolites promote axonal regrowth after Aβ-induced 
axonal atrophy 
To evaluate the effects of brain-penetrating compounds derived from DR on axonal growth, 
we investigated whether they rescued Aβ25−35- or Aβ1−42-induced axonal atrophy in cultured 
cortical neurons. Based on the bioavailability of DR (13 g/kg) in vivo, the concentration of total 
naringenin metabolites in the brain after DR (500 mg/kg) administration was calculated as 13.1 
nM. Thereby, we evaluated the effects of metabolites in vitro at a concentration ranges from 10 
nM to 10 M. Aβ25–35 (10 µM) or Aβ1–42 (5 µM) was administered to cortical neurons after 
3 days incubation, and 3 additional days later, the medium was replaced with fresh medium 
including vehicle or metabolites. After 4 days of compounds administration, neurons were fixed 
with 4% PFA and immunostained for MAP2 and pNF-H. As a result, axonal density was 
significantly decreased by Aβ25−35 or Aβ1−42 treatment. However, naringenin (1 M) and 
naringenin-7-O-glucuronide (0.1 M) significantly promoted axonal regrowth against 
Aβ25−35-induced axonal atrophy (Figure 13A and B). What’s more, Aβ1−42-induced axonal 
atrophy was recovered by naringenin (1 M) and naringenin-7-O-glucuronide (1 and 10 M) 
treatment (Figure 13B). NGF was used as a positive control for axonal elongation after Aβ 
treatment (Kuboyama et al., 2005).  
This result indicates that DR-derived brain penetrating metabolites naringenin and 
naringenin-7-O-glucuronide restore Aβ-induced axonal atrophy. We also evaluated the effects 
of these three metabolites on axonal growth without Aβ treatment, the result was showed in 
Figure 14, naringenin and naringenin-7-O-glucuronide promoted axonal growth compared 
with vehicle-treated group. 
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Figure 13. Effects of the metabolites, naringenin (Nge) and naringenin-7/4’-O-glucuronide 
(Nge-7 or Nge-4’) on axonal and dendritic elongation against Aβ-induced neurite atrophy. 
Cortical neurons were cultured for 3 days, and then 10 µM Aβ25–35, 5 µM Aβ1–42 or vehicle 
(H2O) were administered to the neurons. Three days later, NGF (100 ng/ml), compounds (0.01, 
0.1, 1, 10 μM), or Veh (0.1% DMSO) was treated to neurons after removing Aβ. Neurons were 
immunostained for pNF-H and MAP2 after 4 days treatment. The lengths of the pNF-H or 
MAP2 positive neurites were measured. (A) Representative photos of MAP2-positive dendrites 
and pNF-H-positive axons after Aβ25−35 treatment. (B) Time course of the experiments (upper 
panel). Quantification of axonal and dendrite density per neuron and associated statistics (lower 
panel). The error bars indicate SEM. One-way ANOVA and Dunnett’s post hoc test was 
performed (*p < 0.05, ***p < 0.001 vs. Aβ/Veh; n = 10–40 photographs). 
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Figure 14. Effects of the metabolites, naringenin (Nge) and naringenin-7/4’-O-glucuronide 
(Nge-7 or Nge-4’) on axonal and dendrite growth of normal neurons. Cortical neurons were 
cultured for 3 days, then, NGF (100 ng/ml), compounds (0.01, 0.1, 1, 10 μM), or Veh (0.1% 
DMSO) was treated to neurons. After 4 days treatment, neurons were immunostained for pNF-
H and MAP2. The lengths of the pNF-H positive axons and MAP2 positive dendrites were 
measured. (A) Time course of the experiments (upper panel). (B) Quantification of axonal and 
dendrite density per neuron. The error bars represent SEM. One-way ANOVA and Dunnett’s 
post hoc test was performed (*p < 0.05, **p < 0.01 vs. Cont; n = 19–33 photographs). 
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Naringenin ameliorates memory deficits and AD-like pathology in 5XFAD mice 
As we calculated the contents of naringenin and naringin in DR extract, and naringenin 
could be derived from naringin after metabolism in vivo based on our experiment and other 
reports. The amount of naringenin aglycone in 500 mg DR extract was calculated as 23 mg. 
With the consideration of the dose of naringenin in reports of other AD models (Ghofrani et al., 
2015; Yang et al., 2014), naringenin was orally administered for 31 days at a dose of 5 or 100 
mg/kg per day to the 5XFAD mice (male, 8-12 months old) (Figure 15A). In the object 
recognition test (Figure 15C), compared with vehicle-treated 5XFAD mice, naringenin 100 
mg/kg per day-treated 5XFAD mice and wild-type mice exhibited significantly high 
exploratory frequency to the novel object. In the object location test, high dose of naringenin 
(100 mg/kg per day) showed the trend of improvement of spatial memory (Figure 16A). In the 
open-field test, no significant differences were observed in the distances moved among the four 
groups (Figure 15B). The body weights of mice did not change significantly during drug 
administration (Figure 16B). 
   To investigate the effect of naringenin on AD-like pathologies in 5XFAD mice, we checked 
the expression levels of Aβ plaques and PHF-Tau using immunohistochemical analysis. The 
result was exhibited in Figure 15D, in the wild-type mice, there is no detection of amyloid 
plaques, PHF-tau, or degenerated swollen axons. The amyloid plaques and degenerated swollen 
axons associated with Aβ plaques were significantly reduced in the perirhinal cortex and 
hippocampus of 5XFAD mice after 100 mg/kg naringenin administration. The reduction of 
PHF-tau expression associated with the plaques in the hippocampus was also clarified in 
naringenin (100 mg/kg per day) administered 5XFAD mice. Taken together, these findings 
reveal that naringenin ameliorates memory deficits and effectively induces the reduction of 
amyloid plaques, PHF-tau and swollen axons associated with plaques in 5XFAD mice, as 
demonstrated for DR administration. 
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Figure 15. Recognition memory deficits and AD pathologies were rescued by naringenin 
administration in 5XFAD mice. (A) Time schedule of behavioural test. We orally administered 
naringenin (0, 5, or 100 mg/kg per day) for 29 days to 5XFAD mice (male, 8–12 months old, n 
= 4–5), and evaluated their behavioural performance. (B) Total distance moved (within 10 min) 
in the locomotion open-field test. (C) Object recognition test. The preferential indices for the 
training and test sessions are shown. p = 0.009, drug × time interaction was analysed using 
repeated measures two-way ANOVA, F(3, 11) = 6.24. *p < 0.05 vs. vehicle-treated 5XFAD 
mice, post hoc Bonferroni test. (D) Quantified result of total amyloid plaques, PHF-tau and 
abnormal axons area per 100 µm2 of Aβ plaque in the perirhinal cortex and hippocampus. One-
way ANOVA and Dunnett’s post hoc test were performed in all statistical analyses (*p < 0.05 
vs. vehicle-treated 5XFAD mice). 
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Figure 16. Naringenin ameliorates memory deficits in 5XFAD model mice. (A) Object location 
test. In the training and test sessions, the preferential indices were calculated. Drug × time 
interaction was analysed using repeated measures two-way ANOVA post hoc Bonferroni test. 
(B) The body weight of wild-type mice and 5XFAD mice.  
 
2.3.3 Naringenin targets CRMP2 and regulates the phosphorylation of CRMP2 to 
promote axonal growth 
 
Naringenin binds to its target protein CRMP2 
To investigate the mechanism of naringenin-induced axonal growth and memory 
improvement, firstly, we performed DARTS analysis (Lomenick et al., 2009; Pai et al., 2015) 
to identify a target protein of naringenin. The principle of DARTS analysis is based on the 
conformation changes of the target protein when the ligand binding to it, following a changing 
of the protease sensitivity to the target protein (Lomenick et al., 2009). According to our study, 
DARTS analysis revealed a 62-kDa protein spot was thicker in the DR-treated brain lysate than 
the vehicle on a 2D-PAGE gel after thermolysin reaction (Figure 17), the following MALDI-
TOF/MS analysis identified that the protein was CRMP2. To confirm CRMP2 as a target protein 
of naringenin, we performed DARTS and western blot analyses using cultured cortical neuronal 
lysates (Figure 18A). After thermolysin treatment, the CRMP2 level in naringenin-treated 
lysates was significantly decreased compared with that in vehicle-treated group (Figure 18B).  
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Figure 17. Identification of target proteins of DR extract by DARTS analysis. Mouse brain 
cortex was dissected, and the cortex lysate was added to DR (1 mg/ml) or vehicle solution and 
incubated for 1 h at room temperature. The mixture was proteolysed using thermolysin and 
subjected to 2D-PAGE analysis. The separated proteins were stained. The spot in the DR-treated 
lysate was thicker than that in the vehicle-treated lysate, the spots were cut out and prepared for 
mass spectrometry analysis. 
 
 
Figure 18. Confirmation of CRMP2 as a target protein of naringenin. (A) Protocol of the 
DARTS analysis. (B) DARTS and western blot analysis revealed CRMP2 as a target of 
naringenin. Lysates were made from cultured cortical neurons, vehicle or naringenin was 
rotated with lysates for 1 h at room temperature. The mixture was proteolyzed by thermolysin 
and employed for western blot (Student’s unpaired t-test, *p < 0.05 vs. Veh (T+). The number 
of repeated experiments is shown in each column). 
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Figure 19. Confirmation of CRMP2 as a target of naringenin and naringenin-7-O-glucuronide 
by DARTS and western blot analysis. Mouse cortical neurons (ddY, E14) were cultured for 3 
days, and then neurons were lysed with M-PER solution. Naringenin (Nge, 1.67 mM), 
Naringenin-4’-O-glucuronide (Nge-4’, 1.67 mM), Naringenin-7-O-glucuronide (Nge-7, 1.67 
mM) or vehicle solution was added to the lysates (2.5 g of each), and the solution was rotated 
for 1 h at room temperature. The protein (P) mixture was proteolysed by thermolysin (T, 1.25 
ng or 0.5 ng) in reaction buffer for 15 min at 37°C. EDTA (0.5 M, pH 8.0) was used to stop the 
reaction. The samples were then applied to SDS-PAGE for western blot analysis. 
 
 
 
 
 
40 
 
Since naringenin-7-O-glucuronide promoted axonal growth against Aβ-induced axonal 
atrophy, we speculate that naringenin-7-O-glucuronide also binds to CRMP2. Therefore, we 
performed the DARTS experiment of naringenin and its glucuronides using neuronal lysates. 
The result was exhibited in Figure 19, except for naringenin, naringenin-7-O-glucuronide but 
not naringenin-4’-O-glucuronide also showed decreased band intensity compared with vehicle-
treated lane, which means that naringenin-7-O-glucuronide has the possibility binding to 
CRMP2. This was corresponding to the in vitro assay result, which indicated that naringenin-
induced cellular signalling was attributed to naringenin and naringenin-7-O-glucuronide. 
Next, to confirm the binding of naringenin to CRMP2, we performed immunoprecipitation 
(IP) combined with LC-MS analysis. Firstly, we investigated whether naringenin could be taken 
up by the cultured neurons (Figure 20A), after 0.5, 2, or 6 h of naringenin treatment, the cells 
were lysed and extracted with MeOH, and then the samples were applied to LC-MS analysis. 
The results showed that naringenin was accumulated in the neurons time dependently (Figure 
20B and C). Surprisingly, we also detected naringenin glucuronides existed in the neurons 30 
min after incubation (Figure 20B). Then, the lysates, prepared from neurons that were 
incubated with naringenin for 6 h, were applied to immunoprecipitation with a CRMP2 
antibody or normal IgG antibody (Figure 21). Naringenin was detected significantly higher 
amount using LC-MS after IP with the CRMP2 antibody (peak area: 169,940) but was hardly 
detected in the IgG immunoprecipitated sample (peak area: 8265) (Figure 22A and B). The 
single peak detected in the sample using IgG antibody might be caused by a small amount of 
nonspecific binding between protein G and the CRMP2 protein (Figure 22C). 
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Figure 20. Naringenin could penetrate neuron cell membrane and metabolize to naringenin 
glucuronide. (A) Time course of the experiments. The primary mouse cortical neurons (E14) 
were cultured for three days, and then 100 M naringenin was treated for 0.5, 2, or 6 h. Neuronal 
cells were lysed after washing with 1×PBS for three times, 30 g protein of each was denatured 
and extracted with MeOH, and then was subjected to LC-MS. (B) Naringenin (7.7-7.8 min) and 
naringenin-7/4’-O-glucuronide (5.4-5.5 min) were detected inside of the neurons after 
incubation with naringenin. (C) The amount of naringenin (left panel) or naringenin-7/4’-O-
glucuronide (right panel) in the neurons was determined. 
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Figure 21. Protocol of coupling immunoprecipitation with LTQ-Orbitrap-FT-MS/MS analysis. 
 
 
Figure 22. IP coupled with LC-MS analysis revealed the binding between naringenin and 
CRMP2. Cortical neurons were cultured for 3 days and then were treated with naringenin for 6 
h. (A) Cell lysates were immunoprecipitated with a CRMP2 (upper panel) or normal IgG (lower 
panel) antibody, and the precipitates were extracted with MeOH and applied to LC-MS. (B) 
Peak area of naringenin after IP with CRMP2 or IgG antibody. (C) Immunoprecipatation of 
CRMP2 protein in cultured primary neurons. Primary cultured neurons were maintained for 
three days, in the left figure, cell lysates (30 µg) were treated with protein G beads (20 µl) for 
10 min at 4︒C, protein G beads after boiling were applied to SDS-PAGE, cell lysates (5 g) 
was applied as an input. In the right figure, cell lysates were immunoprecipitated by CRMP2 
antibody (middle lane) or normal IgG (left lane). Cell lysates (3 g) was applied as an input 
(right lane). Western blot was performed by using anti-CRMP2 antibody. 
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To test whether CRMP2 is involved in naringenin-induced axonal elongation, we knocked 
down the expression of CRMP2 using siRNA transfection. Cortical neurons were transfected 
with CRMP2 siRNA (1 M), 3 days later the expression of CRMP2 was evaluated by 
immunocytochemical analysis. As the result, the CRMP2 expression level in the GFP-
transfected neurons was significantly reduced (44%) in CRMP2 siRNA-transfected neurons 
(Figure 23A, right panel). The measured cell body area was not changed between groups 
(Figure 23A, left panel). Naringenin significantly increased the axonal density in control 
siRNA-transfected neurons (Figure 23B, left panel). Nevertheless, after the transfection of 
CRMP2 siRNA, naringenin-induced axonal elongation was completely diminished (Figure 
23B, right panel). These data demonstrate that CRMP2 is a target of naringenin and is involved 
in naringenin-induced axonal growth. 
CRMP2 is reported binding to tubulin heterodimers and responsible for the regulation of 
neurite outgrowth (Fukata et al., 2002). Hyperphosphorylated CRMP2 is expressed in the brain 
of AD patients, and is involved in Aβ-induced deficits of cognitive memory (Cole et al., 2007; 
Gu et al., 2000; Isono et al., 2013; Soutar et al., 2009). CRMP2 is phosphorylated by Cdk5 at 
Ser522 and following phosphorylated by GSK-3β at Thr514, Ser518, and Thr509 (Uchida et 
al., 2005). Therefore, we tested the effect of naringenin on the expression level of 
phosphorylated CRMP2 at the site of pThr514 in Aβ-treated cortical neurons. Compared with 
the control group, CRMP2 was hyperphosphorylated at Thr514 after Aβ25−35 treatment. 
However, naringenin significantly decreased the pCRMP2 level (Figure 23C).  
Taken together, our findings revealed that naringenin targeted to CRMP2 and reduced Aβ-
induced phosphorylation of CRMP2, resulting in axonal growth regulation. 
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Figure 23. CRMP2 mediated naringenin-induced axonal growth. (A) Quantified results of 
CRMP2 level in GFP-positive neurons. Cortical neurons were transfected with siCRMP2 (1 
M) and GFP vector (2 g) for 3 days, then the neurons were immunostained with CRMP2 
antibody. (B) Naringenin-induced axonal growth was diminished by CRMP2 siRNA. Cortical 
neurons were transfected with CRMP2 siRNA (1 M) or control siRNA (1 M) and GFP vector. 
Three days later, 10 M naringenin or vehicle (0.1% DMSO) was treated to the neurons and 
were immunostained for pNF-H for 4 days. The pNF-H-positive axons in the GFP-positive 
neurons were quantified. (C) Aβ-induced CRMP2 phosphorylation was decreased. Mouse 
cortical neurons (E14) were cultured for 3 days. In the immunocytochemical analysis, 10 M 
Aβ25−35 was treated for another 3 days. After Aβ-containing medium was removed, the 
neurons were administered with naringenin (1 M) or vehicle solution (0.1% DMSO) for 0.5, 
24, or 96 h, respectively. The neurons were double immunostained for MAP2 and pCRMP2. 
The pCRMP2 level in neurons was quantified. (A-C) The number of neurons is showed in each 
column. Student’s unpaired t-tests were performed in A and B (*p < 0.05), and one-way 
ANOVA with Dunnett’s post hoc test was performed in C (*p < 0.05 vs. Aβ/Veh at each time 
point). 
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2.4 Discussion and conclusion 
Recently, natural medicines have been highly focused as new direction for treatment of 
dementia. Many groups have reported plant-derived compounds that promote neuritic 
outgrowth (Kim et al., 2014; Orbán-Gyapai et al., 2014) and protect Aβ-induced neuronal death 
(Wang et al., 2009; Zhang et al., 2012). We have emphasized the important effect of recovering 
from Aβ25–35-induced axonal atrophy, and found several natural compounds which promote 
axonal growth, such as withanolide A (Kuboyama et al., 2005), sominone (Kuboyama et al., 
2006), icariin (Urano and Tohda, 2010) and diosgenin (Tohda et al., 2012). What’s more, those 
active compounds also attenuate memory deficits in AD model mice. While in the present study, 
we have found for the first time that the water extract of DR signiﬁcantly enhanced the axonal 
regrowth after Aβ25–35-induced atrophy (Figure 1). In the in vivo study, after 31 days of DR 
extract oral administration to the 5XFAD mice, the recognition memory and spatial memory 
deficits were rescued (Figures 4 and 5). The AD derived pathologies, such as Aβ plaques, PHF-
tau, and degenerated axons, were also ameliorated after DR administration (Figures 7 and 8).  
For exploring of the mechanism of natural medicines, it is necessary to know the effective 
compounds existed in or derived from them after oral administration. Generally speaking, it is 
time-consuming and complicated to isolate, identify, and screen the effective compounds in 
natural medicines. Besides, it is possible that the components can be metabolized to phase I and 
II derivatives following administration. What’s more, to develop therapeutic compounds as 
CNS drugs, it is indispensable to consider the bioavailability and access of metabolites or 
natural compounds to brain tissues. Thus, the metabolites that have been identified in the target 
tissues must be used to investigate the bioactivity and physiological mechanisms of natural 
medicines. Here, we construct a new strategy to explore therapeutic candidates for AD from 
natural medicines by coupling biochemical analysis with pharmacological methods. We 
identified metabolites that were delivered into the brain after DR administration. To detect a 
variety of metabolites as possible as we can, we administered a high single dose of DR (13 g/kg) 
to the 5XFAD mice. As a result, comprehensive LTQ-Orbitrap-FT-MS/MS analysis revealed 
only 3 metabolites (naringenin and naringenin-4’/7-O-glucuronide) identified in the brain 
cortex (Figure 12). We then tested the effects of these metabolites on Aβ25–35 or Aβ1–42-
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induced axonal atrophy in cultured cortical neurons. As a consequence, naringenin and 
naringenin-7-O-glucuronide, but not naringenin-4’-O-glucuronide can restore Aβ-induced 
axonal atrophy (Figure 13). 
UDP-glucuronosyltransferases (UGTs) are involved in glucuronidation and mediated in 
an important metabolic pathway that facilitates the clearance of xenobiotics, including drugs 
and environmental chemicals, and metabolism of exogenous and endogenous compounds 
(Rowland et al., 2013). Usually these hydrophilic glucuronides are considered as inactive and 
poor BBB permeability, however, some glucuronides, such as quercetin-3-O-glucuronide and 
morphine-6-glucuronide, can be delivered to the brain and show important biological activities 
(Ho et al., 2013; Klimas and Mikus, 2014). Our present report also shows that naringenin-7-O-
glucuronide can across the BBB and enhance axonal growth. How do these glucuronides across 
the BBB and function in the brain? One of the explanations is the expression of transporters at 
the BBB. The organic anion transporter (OAT) is localized at the membrane of endothelial cells 
and is involved in the transportation of kinds of endogenous and xenobiotic amphipathic 
compounds (Kullak-Ublick et al., 2001; Ohtsuki et al., 2004; Sugiyama et al., 2003). Moreover, 
OAT actively transported morphine-6-glucuronide across the BBB to the brain (Bourasset et al., 
2003). However, there are no reports with a regard to a naringenin-glucuronide transporter. 
Another explanation is the existence of UGTs in the brain and neurons. UGTs are mainly 
expressed in astrocytes and endothelial cells of the BBB in the brain, (Ouzzine et al., 2014). 
Furthermore, the glucuronosyltransferase isoform UGT1A6 was reported existed in primary 
cultures of astrocytes and neurons (Suleman et al., 1998). The presence of UGTs in neurons is 
also proved in our results (Figure 20). Thus, it is possible that naringenin was absorbed by 
neurons and glucuronidated by UGTs after penetrating the BBB. 
DARTS has been employed for the identification of ligand targets, based on the alterations 
of protein conformation following changes of proteolytic sensitivity that occur after the binding 
of ligand with its receptor (Lomenick et al., 2009). Therefore, this method will be an important 
tool to identify new targets for the interventions of AD. In the present study, we are the first 
combining DARTS method with LTQ-Orbitrap-FT-MS/MS analysis to discover a brain-
acrossed compound, naringenin, and its target protein CRMP2 to clarify the mechanism of a 
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natural medicine. As a matter of fact, DARTS is based on the conformational changes after 
ligands binding, resulting in an increase or a decrease in proteolytic susceptibility of the target 
protein (Lomenick et al., 2009). In this thesis, compared with vehicle treated thermolysin group, 
DR showed increased band density (Figure 17) while naringenin showed decreased band 
density of CRMP2 (Figure 18) in DARTS analysis. This probably due to non-specifically 
binding of DR-derived components (besides naringenin) with CRMP2, resulting in the different 
conformational changes of CRMP2 with that of CRMP2 induced by naringenin. It is possible 
that naringenin-7-O-glucuronide binds to CRMP2 since naringenin-7-O-glucuronide showed 
the effect of axonal growth against Aβ-induced axonal atrophy. Our DARTS results showed 
that except for naringenin, naringenin-7-O-glucuronide but not naringenin-4’-O-glucuronide 
also exhibited the binding possibility to CRMP2 (Figure 19), which was corresponding to the 
assay result in vitro. 
The neuroprotective effects against H2O2-induced hyper-oxidation (Heo et al., 2004; 
Vafeiadou et al., 2009) and anti-inﬂammatory activity in LPS/IFN-γ-stimulated glial cells were 
reported by treatment of naringenin. Some other reports also showed that learning and memory 
was improved by naringenin in Aβ or streptozotocin-injected AD models (Ghofrani et al., 2015; 
Yang et al., 2014), which was related to the mitigation of lipid peroxidation and apoptosis or 
the increased insulin and insulin receptor expression in the rat brain. However, it remains 
unknown that naringenin induces axonal growth, and the specific target protein of naringenin 
relates to the memory recovery. In this thesis, we clarified that axonal growth was enhanced by 
naringenin in both normal and Aβ-treated neurons following axonal atrophy (Figure 13 and 14). 
This axonal growth is mediated by CRMP2 protein and probably contributes to the neural 
networks reconstruction and memory improvements.  
CRMP2 is important for the regulation of neurite outgrowth owing to its binding to tubulin 
heterodimers (Fukata et al., 2002), CRMP2 knockout mice showed abnormal NMDA receptor 
expression, disrupted dendrite development and defective synapse formation in CA1 neurons 
and impaired learning and memory (Nakamura et al., 2016; Zhang et al., 2016). Using CRMP2 
siRNA, 90% knockdown of CRMP2 led to a 37% decrease in total neurite outgrowth compared 
with control in cultured cortical neurons (Wilson et al., 2014). In our experiment, 44% 
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knockdown of CRMP2 led to a slightly decrease of axonal length (9%), and cancelled 
naringenin-induced axonal growth (Figure 23A and B), which indicated that naringenin-
induced axonal growth is mediated by CRMP2. The binding of small ligands to CRMP2 has 
rarely been reported except for lacosamide, in vitro and in vivo study of lacosamide showed that 
the association between Cdk5-phosphorylated CRMP2 and CaV2.2 was reduced (Moutal et al., 
2016). What’s more, lacosamide prevents the growth of neurites is mediated by inhibition of 
CRMP2-dependent tubulin polymerization. Intraventricular injection of Aβ25−35 peptide 
caused impairment of novel object recognition memory and induced CRMP2 phosphorylation 
in normal mice. However, the effect of Aβ25−35-induced memory deficits was diminished in 
CRMP2 phosphorylation-deficient knock-in mice (Isono et al., 2013). This data corresponds to 
our result, which the reduction of CRMP2 phosphorylation level induced by naringenin 
contributes to memory function recovery. Increased phosphorylation of Thr514-CRMP2 
correlates with Aβ burden and synaptic deficits in Lewy body dementias (Xing et al., 2016). 
Phosphorylated CRMP2 is also reported colocalized with PHF-tau aggregates in triple-
transgenic AD model mice (Watamura et al., 2015). It is possible that decrease of 
phosphorylated CRMP2 contribute to the amelioration of Aβ plaques and PHF-tau aggregation. 
The present study is the first to report a compound, naringenin, that binding to CRMP2 and 
inhibits CRMP2 phosphorylation at the site of Thr514 (Figure 23C). The association between 
CRMP2 and tubulin is probably restored by naringenin, and which contribute to axonal growth 
and memory function recovery. 
In conclusion, it is the first report showing that DR enhances memory function and 
ameliorates AD pathologies in 5XFAD mice. LTQ-Orbitrap-FT-MS/MS and DARTS analysis 
pinpointed the brain active compounds in DR-treated mice and identified CRMP2 as a target 
protein of them. Naringenin and naringenin-7-O-glucuronide probably are novel regulators of 
CRMP2, which is involved in axonal growth and contributes to memory improvement.  
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Chapter 2 
Bioassay-guided isolation of active constituents from DR and their effects on Aβ-induced 
axonal atrophy 
 
3.1 Introduction 
   Natural medicines and botanical sources have been focused in the last decades as an 
important group for new drug discovery (Pan et al., 2013). Bioassay-guided fractionation of the 
medicinal plants is usually seen as the way leading to bioactive druggable compound as the 
new drug (Katiyar et al., 2012). This method is also widely used for the isolation of bioactive 
compounds from herbal medicines for neuroprotection (Park and Kim, 2002; Xian et al., 2012). 
However, as we mentioned in Chapter 1, some disadvantages should be cared, because such as 
the bioassay-guided in vitro screening neglects the bio-metabolism of constituents before and 
after absorption, and ignores tissue distribution especially for CNS diseases (blood-brain-
barrier permeable or not).  
   In chapter 1, we established a systematic strategy to get the effective compounds and clarify 
their mechanism in the target tissue, brain. Compared with the ordinary bioassay-guided in vitro 
screening, we think our method is reasonable and efficient to get authentic active compounds 
because considered bio metabolism and tissue distribution. Since DR extract showed axonal 
growth effect after Aβ-induced axonal atrophy, we are interested in which compounds are 
shown as active constituents by bioassay-guided in vitro screening. Therefore, we performed 
this experiment to compare the ordinary method with the strategy aforementioned in chapter 1. 
 
3.2 Materials and methods 
3.2.1 General experimental procedures 
   The optical rotations were recorded on a JASCO P-2000 polarimeter at room temperature. 
The UV spectra were measured on a JASCO V-630 spectrophotometer, with the CD spectra 
being recorded on a JASCO J-805 spectropolarimeter. The NMR spectra were acquired on a 
JEOL ECX400 spectrometer. The mass spectra were obtained using a Bruker Esquire 3000 Plus 
mass spectrometer, equipped with an ESI ion source operating in the positive/negative-ion 
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mode. Column chromatography (CC) was performed with silica gel (60 N, 63-210 μm, Kanto 
Chemical, Tokyo, Japan) and Sephadex LH-20 (Amersham Pharmacia Biotech AB, Björkgatan, 
Sweden). TLC analysis was performed on silica gel plates (Merck, Darmstadt, Germany). We 
used analytical grade chemical reagents from Kanto Chemical (Osaka, Japan), and the LC-MS 
grade chemical reagents were purchased from Wako Pure Chemical Industries (Tokyo, Japan). 
 
3.2.2 Extraction and isolation. 
   The rhizomes (772 g) of Drynaria fortunei were extracted with 15.4 L of water, heated for 
15 min until boiling, boiled for 1 h, filtered, and freeze-dried under reduced vacuum to yield an 
aqueous extract (60.2 g, 7.8% yield). The extract was suspended in water (180 ml), and 
successively partitioned with petroleum ether (p.e.) (60−90 °C, 3 × 540 ml), ethyl acetate 
(EtOAc) (3 × 540 ml), and n-butanol (BuOH) (3 × 540 ml). The dried petroleum ether, EtOAc, 
n-BuOH, and water fractions (0.87, 2.25, 7.86, and 41.3 g, respectively) were obtained after 
removal of the solvent. Ten-milligram samples of each fraction were dissolved in DMSO for 
the bioassay. 
   The n-BuOH fraction (7.77 g) was fractionated by silica gel CC (60N, 195 g; column: 45 
mm × 500 mm) eluted with chloroform (CHCl3)−MeOH [10:1 (1.7 L), 4:1 (2.5 L), 2:1 (2.4 L), 
1:1 (1.5 L), 1:4 (1 L), MeOH (1 L)] to yield fractions 1−10. Fraction 5 (325 mg) was further 
fractionated by silica gel CC (60N, 30 g) with CHCl3−MeOH (5:1, 2.5:1) to yield six 
subfractions, of which fraction 5-4 was purified by Sephadex LH-20 using MeOH to yield 
compound 5 (33.0 mg). Fraction 6 was purified by passage over a Sephadex LH-20 column 
with MeOH, then recrystallized from MeOH to yield compound 1 (285.3 mg). Fraction 8 was 
further separated using a Sephadex LH-20 column with MeOH to yield three subfractions, of 
which fraction 8-1 was subjected to silica gel CC with CHCl3−MeOH−H2O (3:1:0.2, 2:1:0.2) 
to give five fractions. Recrystallization of fraction 8-1-3 from MeOH yielded compound 3 (35.0 
mg). Fraction 8-2 was further fractionated by silica gel CC with CHCl3−MeOH−H2O (3:1:0.2, 
2:1:0.2) to provide four fractions, of which fraction 8-2-3 was purified over a Sephadex LH-20 
column with MeOH, then recrystallized from MeOH to yield compound 2 (121.0 mg). Fraction 
9 was further subjected to silica gel CC with CHCl3−MeOH−H2O (2:1:0.2, 0:1:0) to provide 
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five fractions, of which fraction 9-1 was purified by Sephadex LH-20 using MeOH to yield 
compound 4 (18.0 mg). (2S)-Naringin (1): [α]25D −88 (c 0.5, MeOH); UV (MeOH) λmax (log 
ε) 213 (4.47), 283 (4.24) nm; ECD (0.10 mM, MeOH) λmax (Δε) 215 (+17), 286 (−27) nm; 
(2S)-neoeriocitrin (2): [α]25D −92 (c 2.5, MeOH); UV (MeOH) λmax (log ε) 282 (4.25); ECD 
(0.10 mM, MeOH) λmax (Δε) 222 (+28), 289 (−53) nm. 
 
3.2.3 LC-MS analysis of the main components from DR extracts and n-BuOH subfraction 
   Qualitative analysis of five isolated compounds (1−5) was conducted using LC-MS analysis. 
The DR aqueous extract and the n-BuOH fraction were dissolved in 5% MeOH to yield final 
solutions of 5 and 10 mg/ml, respectively. Each compound was weighed exactly and dissolved 
in MeOH for a stock solution of 1.0 mg/ml and diluted with 5% MeOH to a final concentration 
of 180 μg/ml. Both samples were filtered through a 0.45 μm membrane, and 10 μL was injected 
for LC-MS analysis. 
An Agilent 1100 HPLC system (Agilent Technologies, Palo Alto, CA, USA) equipped with 
a Bruker Esquire 3000 Plus mass spectrometer was used. The analysis was performed using a 
Capcell Pak C18 MGIII S-5 (1.5 mm i.d. × 150 mm, Shiseido) column at a temperature of 25°C. 
The binary mobile phase consisted of (A) 0.1% (v/v) formic acid in water and (B) acetonitrile; 
a gradient elution was conducted under the following conditions: 0 min, 6% B; 7 min, 6% B; 
10 min, 12% B; 20 min, 20% B; 35 min, 30% B; 36 min, 6% B; 42 min, 6% B. The flow rate 
was 0.2 ml/min. Photodiode array detection was performed between the wavelengths of 190 
and 400 nm. 
 
3.2.4 Primary cultures and measurement of axonal density 
   Mouse primary cortical neurons were cultured as described in Chapter 1. 
   The neurons were treated with 10 μM Aβ25−35 (Sigma-Aldrich) for 3 days. Aβ25−35, an 
active fragment of Aβ, was preincubated for 4 days at 37 °C for aggregation. Three days after 
the treatment, the Aβ25−35-containing medium was removed, and the neurons were treated 
with fresh medium including DR extracts sub-fractions, isolated compounds, or vehicle (0.1% 
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DMSO) for 4 days. The D. fortunei extracts and fractions were diluted to the final 
concentrations of 1 and 10 μg/ml, whereas the other compounds were prepared at 1 and 10 μM 
concentrations (0.1% DMSO). NGF (100 ng/ml; Alomone, Jerusalem, Israel) served as a 
positive control. The cells were fixed with 4% paraformaldehyde for 1 h and immunostained 
with a monoclonal antibody against pNF-H, an axonal marker (1:500, SMI-35). A polyclonal 
antibody against MAP2 (1:2000, Abcam) was used as a neuronal marker. Alexa Fluor 594-
conjugated goat anti-mouse IgG (1:200) and Alexa Fluor 488-conjugated goat anti-rabbit IgG 
(1:200) were used as the secondary antibodies (Molecular Probes). The nuclear counter staining 
was performed using DAPI (1 μg/ml, Sigma-Aldrich). The fluorescent images were captured at 
644 μm × 855 μm by a fluorescent microscope system (BX-61/DP70, Olympus, Tokyo, Japan). 
The lengths of the pNF-H-positive axons were measured using a MetaMorph analyzer 
(Molecular Devices, Sunnyvale, CA, USA), which automatically traced and measured the 
neurite lengths without measuring the cell bodies. The numbers of neurons were counted by 
overlapped stains of MAP2 and DAPI. The total length of the axons was divided by the number 
of MAP2-positive neurons. 
 
3.2.5 Statistical analysis 
   The statistical comparisons were performed by one-way analysis of variance (ANOVA) 
with post hoc Dunnett’s test using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). 
Values of p < 0.05 were considered significant. The values of the data were expressed as the 
means ± SEM. 
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3.3 Results  
3.3.1 Bioassay-guided fractionation and isolation of compounds from DR extract 
   As we have investigated that DR extract rescued Aβ25−35-induced axonal atrophy, to 
investigate the active constituents that were present, four fractions (petroleum ether, ethyl 
acetate, n-BuOH, and water fractions) were obtained from the initial crude plant extract, and 
their effects on Aβ25−35-induced axonal atrophy were evaluated (Figure 24). The n-BuOH 
fraction (10 μg/ml) induced axonal outgrowth after the Aβ25−35 treatment, whereas the 
petroleum ether, ethyl acetate, and water fractions did not show any significant effects on 
Aβ25−35-induced axonal atrophy. 
   To determine which constituents are effective against axonal atrophy, the bioactive n-BuOH 
fraction was subjected to chromatographic purification. The isolation process was showed in 
Figure 25. Five compounds were isolated and identified as (2S)-naringin (1) (Maltese et al., 
2009), (2S)-neoeriocitrin (2) (Li et al., 2006), 5,7-dihydroxychromone-7-O-neohesperidoside 
(3) (Bhardwaj et al., 1982), caffeic acid-4-O-glucoside (4) (Nishimura et al., 1995), and 
protocatechuic acid (5) (Lee et al., 2012). The compounds were identified by comparing their 
spectroscopic data with those reported in the literature and the structures were showed in Figure 
26. The NMR data of compounds 1-5 were showed in Tables 2-6, and the absolute 
configurations of compounds 1 and 2 were determined by comparing their CD curves (Figure 
27) with the reported values. 
   The presence of the isolated compounds was confirmed in the DR extract and the n-BuOH 
fraction by LC-MS analysis, and an HPLC chromatogram (Figure 28) showed that compounds 
1 and 2 were the major constituents detected along with the relatively minor compounds 3−5 in 
the n-BuOH fraction. 
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Figure 24. Effects of subfractions of DR on axonal and dendrite extension after Aβ25–35-
induced neurite atrophy. Cortical neurons were cultured for three days, and then cells were 
treated with (Veh) or without (Cont) 10 µM Aβ25–35. Three days later, each fraction (1 or 10 
µg/ml), NGF (100 ng/ml), or Veh (0.1% DMSO) was added to neurons after removing Aβ25–
35. Four days after treatment, the neurons were fixed and immunostained for pNF-H and MAP2. 
The lengths of pNF-H and MAP2 positive neurites per neuron were measured. Values are means 
± SEM of data. [*p < 0.05, ***p < 0.001 vs. Veh (one-way ANOVA post hoc Dunnett’s test, n 
= 30-60 photographs)]. Scale bar = 200 µm. 
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Figure 25. Process of isolation from n-BuOH fraction of DR extract. 
 
 
 
Figure 26. Structures of isolated compounds 1-5. 
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Figure 27. CD spectra of compounds 1 and 2. 
 
 
 
Figure 28. HPLC maxplot (190-400 nm) chromatograms of the DR extract (upper) and n-
BuOH fraction (lower). Compounds 1-5 were detected in the both fractions, which were 
isolated and chemically identified mainly by the spectroscopic methods. 
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Table 2. 1H, 13C spectra of (2S)-naringin (1) (CD3OD, 400 MHz) 
position H (J in Hz) C (type) 
2 5.37, dd (12.8, 2.3) 80.7, CH 
3 
3.14, dd (12.8, 17.4) 
2.74, dd (2.3, 17.4) 
44.0, CH2 
4  198.5, C 
5  164.7, C 
6 6.15, d (2.3) 97.8, CH 
7  166.6, C 
8 6.17, d (2.3) 96.7, CH 
9  164.6, C 
10  104.9, C 
1’  130.9, C 
2’, 6’ 7.31, d (8.7) 129.1, CH 
3’, 5’ 6.80, d (8.7) 116.3, CH 
4’  159.1, C 
1’’ 5.09, d (8.0) 99.3, CH 
2’’ 3.63, dd (8.0, 7.0) 79.0, CH 
3’’ 3.58, dd (10.0, 7.0) 78.9, CH 
4’’ 3.38, dd (10.0, 9.0) 71.2, CH 
5’’ 3.42, dd (9.0, 6.2) 78.1, CH 
6’’ 
3.85, m 
3.68, m 
62.3, CH2 
1”’ 5.23, d (1.8) 102.5, CH 
2”’ 3.93, dd (2.0, 3.0) 72.2, CH 
3”’ 3.58, dd (10.0, 3.0) 72.2, CH 
4”’ 3.38, dd (10.0, 10.0) 73.9, CH 
5”’ 3.88, dq (10.0, 6.0) 70.0, CH 
6”’ 1.28, d (6.0) 18.2, CH3 
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Table 3. 1H and 13C spectra of (2S)-neoeriocitrin (2) (CD3OD, 400 MHz) 
position H (J in Hz) C (type) 
2 5.31, dd (12.4, 3.2) 80.7, CH 
3 
3.11, dd (12.4, 17.4) 
2.75, dd (3.2, 17.4) 
44.0, CH2 
4  198.5, C 
5  164.6, C 
6 6.14, d (2.3) 97.8, CH 
7  166.6, C 
8 6.17, d (2.3) 96.8, CH 
9  165.0, C 
10  102.5, C 
1’  131.5, C 
2’ 6.91, s 114.8, CH 
3’  146.8, C 
4’ 146.5 146.5, C 
5’ 6.77, m 116.2, CH 
6’ 6.75, m 119.3, CH 
1’’ 5.09, d (7.8) 99.3, CH 
2’’ 3.62, dd (3.8, 7.8) 79.0, CH 
3’’ 3.58, dd (3.8, 10.0) 78.9, CH 
4’’ 3.38, dd (10.0, 9.0) 71.2, CH 
5’’ 3.42, dd (9.0, 6.2) 78.1, CH 
6’’ 
3.85, m 
3.68, m 
62.3, CH2 
1”’ 5.23, d (1.8) 99.4, CH 
2”’ 3.92, dd (1.8, 3.6) 72.2, CH 
3”’ 3.58, dd (10.0, 3.6) 72.2, CH 
4”’ 3.38, dd (10.0, 10.0) 73.9, CH 
5”’ 3.88, dq (10.0, 5.9) 70.0, CH 
6”’ 1.28, d (6.4) 18.2, CH3 
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Table 4. 1H, 13C, HMBC, COSY spectra of 5,7-dihydroxychromone-7-O-neohesperidoside (3) 
(CD3OD, 400 MHz) 
position H (J in Hz) C (type) HMBC COSY 
2 8.04, d (6.0) 158.7, CH 3, 9, 4 H-3 
3 6.25, d (6.0) 112.0, CH 2, 4, 10 H-2 
4  183.6, C   
5  163.2, C   
6 6.46, d (2.4) 101.0, CH 8, 10, 5 H-8 
7  164.5, C   
8 6.65, d (2.4) 96.0, CH 6, 10, 9, 7 H-6 
9  159.5, C   
10  108.3, C   
1’ 5.17, d (7.2) 99.7, CH 7 H-2’ 
2’ 3.67, dd (7.2, 9.6) 78.9, CH 3’, 1’, 1”  
3’ 3.59, t (9.6) 79.1, CH 2’, 4’  
4’ 3.40, dd (1.2, 9.6) 71.3, CH 5’ 6’ H-5’ 
5’ 
3.50, dddd (2.0, 5.6, 
10.0) 
78.2, CH  H-6’ 
6’ 
3.88, m 
3.63, m 
62.3, CH2 4’ H-5’ 
1” 5.26, d (2.0) 102.6, CH  H-2” 
2” 3.93, dd (2.0, 3.2) 72.2, CH 3”, 4” H-1”, 3” 
3” 3.58, m 72.2, CH 3”, 6” H-2”, 4” 
4” 3.36, dd (8.0, 10.0) 73.9, CH 6”, 5”, 3” H-3”, 5” 
5” 3.89, m 70.0, CH 3”, 4” H-4”, 6” 
6” 1.30, d (5.6) 18.2, CH3 4”, 5” H-5” 
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Table 5. 1H, 13C spectra of caffeic acid-4-O-glucoside (4) (CD3OD, 400 MHz) 
position H (J in Hz) C (type) 
1  131.7, C 
2 7.07, d (1.8) 118.2, CH 
3  148.5, C 
4  148.4, C 
5 7.18, d (8.0) 120.0, CH 
6 7.01, dd (1.8, 8.0) 121.8, CH 
1’ 7.46, d (16.0) 144.5, CH 
2’ 6.32, d (16.0) 115.7, CH 
3’  172.1, C 
1’’ 4.83, d (7.2) 103.6, CH 
2’’ 3.50, t (7.2) 77.6, CH 
3’’ 3.47, t (7.2) 74.8, CH 
4’’ 3.40, t (8.0) 71.3, CH 
5’' 3.45, m 78.4, CH 
6’’ 
3.71, dd (12.0, 5.0) 
3.90, dd (12.0, 2.2) 
62.4, CH2 
 
Table 6. 1H, 13C spectra of protocatechuic acid (5) (CD3OD, 400 MHz) 
position H (J in Hz) C (type) 
1  123.1, C 
2 7.43, d (1.8) 117.7, CH 
3  146.1, C 
4  151.5, C 
5 6.78, d (8.4) 115.7, CH 
6 7.41, dd (1.8, 8.4) 123.9, CH 
C=O  170.3, C 
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3.3.2 Bioassay-guiding isolated compounds promote axonal growth 
   To validate the axonal regrowth effects of the isolated compounds, we investigated their 
recovery effects on Aβ25−35-induced axonal atrophy in cultured cortical neurons. Axonal 
atrophy from the Aβ25−35 treatment was observed, a finding that was similar to previous results. 
Compounds 2 (1 and 10 μM) and 4 (10 μM) showed axonal regrowth effects on Aβ25−35-
induced atrophy (Figure 29). 
 
 
Figure 29. Effects of isolated compounds on axonal and dendrite extension against Aβ25−35-
induced neurite atrophy. The cortical neurons were cultured for 3 days, and then the cells were 
treated with (Veh) or without (Cont) 10 μM Aβ25−35. Three days later, each of the compounds, 
1−5 (1 or 10 μM), NGF (100 ng/ml), or Veh (0.1% DMSO) was added to the neurons after 
removing the Aβ25−35. Four days after the treatment, the neurons were fixed and 
immunostained for pNF-H and MAP2. The lengths of pNF-H and MAP2 positive neurites per 
neuron were measured. The values are the means ± SEM of the data [*p < 0.05, **p < 0.01, 
***p < 0.001 vs Veh, (one-way ANOVA post hoc Dunnett’s test, n = 15−20 photographs)]. 
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3.4 Discussion and conclusion 
   Using bioassay-guided isolation, we successfully identified 5 main compounds in DR water 
extract, and especially neoeriocitrin and caffeic acid-4-O-glucoside (two of them) showed 
effects on axonal growth against Aβ25−35-induced atrophy (Figure 29) (Yang et al., 2015). 
Among 5 compounds contained in n-BuOH fraction, naringin, neoeriocitrin, 5,7-
dihydroxychromone-7-O-neohesperidoside, caffeic acid-4-O-glucoside were detected in 
5XFAD mice plasma after oral administration of DR (Table 1). However, those 4 compounds 
were not detected in the brain. It demonstrates that candidate compounds obtained by bioassay-
guided screening do not consist with in vivo screening performed in chapter 1. Although 
naringenin and naringenin-7-O-glucuronide, two metabolites of naringin, were shown as brain 
transferred active compounds in chapter 1, metabolites cannot be suggested in the extract-based 
in vitro assay from the beginning.  
The traditional way to get effective compounds from crude drugs is performing bioassay-
guided isolation. However, it is very time-consuming and needs much amount of starting 
extracts for isolation of pure compounds, the most importantly, has a risk of false-positive due 
to the ignoration of drug bio-metabolism and tissue distribution. Our method described in 
chapter 1 can directly identify substances which are delivered to the brain or even other target 
tissues after administration of crude extracts. It is worth noting that our method established in 
chapter 1 is based on the MS/MS analysis of compounds, this method may not be appropriately 
applied to the natural plants that the components were never reported before. Nevertheless, 
most of the components of traditional medicines were well studied, so it is not necessary to 
repeat the work of bioassay-guided isolation. Therefore, our in vivo screening method may be 
a fast, direct, and efficient way to identify effective metabolites for use as interventions for AD. 
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4. Summary 
Alzheimer’s disease (AD) is a severe progressing neurodegenerative disorder. Most AD 
cases occur sporadically, APP and PS1 gene mutations cause a small percentage of familial 
early-onset AD cases. However, the Aβ plaques and neurofilament tangles are the common 
characteristics of them. The amount of the pathologic Aβ1−42 isoform is increased underlying 
APP/PS1 gene mutations and rapidly form Aβ fibrils. Several reports showed that intraneuronal 
accumulation of Aβ is followed by axonal degeneration, which induces synaptic reduction, 
neuronal circuits disruption and memory deficits further. Thereby, we consider that axonal 
regeneration is contributed to reconstruction of neuronal networks and recovery of memory 
function.  
In vitro experiments indicated that Drynaria rhizome (DR) extract promoted axonal 
regrowth after Aβ-induced axonal atrophy. In vivo result showed that memory deficits were 
ameliorated after oral administration of DR extract, and the hallmark of AD, Aβ plaques, PHF-
tau and degenerated swollen axons, were also reduced. In order to clarify the mechanism of DR 
induced axonal growth and memory improvement, firstly we investigated the effective 
compounds derived from DR extract. Compared with the ordinary bioassay-guided isolation, 
the in vivo screening showed the advantages to narrow candidates of active compounds and 
efficient to get the authentic active compounds with the consideration of drug bio metabolism 
and tissue distribution. As the result, naringenin and naringenin glucuronides were detected 
from the brain after DR extract administration and showed axonal regrowth activity in primary 
cultured cortical neurons. Further in vivo study indicated that naringenin enhances memory 
recovery and reduces Aβ plaques, PHF-tau and degenerated axons, meaning that naringenin and 
its metabolites were likely the active compounds derived from DR extract. As a mechanism of 
naringenin-induced axonal regeneration, we identified CRMP2 as the target protein of 
naringenin. Using CRMP2 siRNA knockdown experiment in the cultured cortical neurons, 
naringenin-induced axonal growth was completely diminished by knockdown of CRMP2, 
which indicated that naringenin-induced axonal growth signaling was mediated by CRMP2. 
We also found that Aβ-induced hyperphosphorylation of CRMP2 was significantly decreased 
by naringenin treatment in cultured cortical neurons. These results suggest that naringenin-
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induced axonal regeneration, leading to the reconstruction of neuronal network, and contributes 
to memory recovery in AD model mice. 
To confirm the superiority of the in vivo screening method established in this study 
compared with ordinary bioassay-guided isolation, we performed the isolation of active 
compounds from DR extract using the ordinary way. As a result, neoeriocitrin and caffeic acid-
4-O-glucoside showed the activity of axonal elongation against Aβ-induced axonal atrophy. 
However, these two compounds failed to penetrate blood-brain-barrier, which indicated that our 
method shown in chapter 1 is an efficient way to get authentic active compounds from natural 
medicines with the consideration of drug bio metabolism and tissue distribution. 
In conclusion, it is the first report that DR ameliorates AD pathologies and enhances 
memory function in 5XFAD mice. LTQ-Orbitrap-FT-MS/MS coupling with DARTS analysis 
pinpointed the effective authentic compounds derived from DR and identified CRMP2 as a 
molecule that binds to the active compound. This systematic strategy must contribute to the 
development of natural medicines and exploration of their mechanisms. Moreover, this strategy 
can be broadly applied to the identification of novel compounds and targets for intervention in 
CNS diseases. 
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